Advertisement

Infectious Diseases and the Kidney

  • Jethro Herberg
  • Amitava Pahari
  • Sam Walters
  • Michael Levin
Reference work entry
  • 2.1k Downloads

Abstract

The kidney is involved in a wide range of bacterial, viral, fungal, and parasitic diseases. In most systemic infections, renal involvement is a minor component of the illness, but in some, renal failure may be the presenting feature and the major problem in management. Although individual infectious processes may have a predilection to involve the renal vasculature, glomeruli, interstitium, or collecting systems, a purely anatomic approach to the classification of infectious diseases affecting the kidney is rarely helpful because most infections may involve several different aspects of renal function.

Keywords

Nephrotic Syndrome Severe Acute Respiratory Syndrome Disseminate Intravascular Coagulation Hemolytic Uremic Syndrome Hemorrhagic Fever 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

The kidney is involved in a wide range of bacterial, viral, fungal, and parasitic diseases. In most systemic infections, renal involvement is a minor component of the illness, but in some, renal failure may be the presenting feature and the major problem in management. Although individual infectious processes may have a predilection to involve the renal vasculature, glomeruli, interstitium, or collecting systems, a purely anatomic approach to the classification of infectious diseases affecting the kidney is rarely helpful because most infections may involve several different aspects of renal function. In this chapter, a microbiologic classification of the organisms affecting the kidney is adopted. Although they are important causes of renal dysfunction in infectious diseases, urinary tract infections and hemolytic uremic syndrome (HUS) are not discussed in detail because they are considered separately in Chapters 54 and 48 respectively.

Elucidation of the cause of renal involvement in a child with evidence of infection must be based on a careful consideration of the geographic distribution of infectious diseases in different countries. A history of foreign travel; exposure to animals, insects, or unusual foods or drinks; outdoor activities such as swimming or hiking; and contact with infectious diseases must be sought in every case. The clinical examination should include a careful assessment of skin and mucous membranes and a search for insect bites, lymphadenopathy, and involvement of other organs. A close collaboration with a pediatric infectious disease specialist and hospital microbiologist will aid the diagnosis and management of the underlying infection.

A tantalizing clue to the pathogenesis of glomerular disease is the marked difference in the incidence of nephrosis and nephritis in developed and underdeveloped areas of the world. In several tropical countries, glomerulonephritis (GN) accounts for up to 4% of pediatric hospital admissions; the incidence in temperate climates is 10- to 100-fold less. This difference might be explained by a complex interaction of several different factors, including nutrition, racial and genetically determined differences in immune responses, and exposure to infectious diseases. A growing body of evidence, however, suggests that long-term exposure to infectious agents is a major factor in the increased prevalence of glomerular diseases in developing countries.

Renal involvement in infectious diseases may occur by a variety of mechanisms: direct microbial invasion of the renal tissues or collecting system may take place in conditions such as staphylococcal abscess of the kidney as a result of septicemic spread of the organism or as a consequence of ascending infection; damage to the kidney may be caused by the systemic release of endotoxin or other toxins and activation of the inflammatory cascade during septicemia or by a focus of infection distant from the kidney; ischemic damage may result from inadequate perfusion induced by septic shock; the kidney may be damaged by activation of the immunologic pathways or by immune complexes resulting from the infectious process. In many conditions, a combination of these mechanisms may be operative. In the assessment of renal complications occurring in infectious diseases, the possibility of drug-induced nephrotoxicity caused by antimicrobial therapy should always be considered. The nephrotoxic effects of antibiotics and other antimicrobial agents are not addressed in this chapter but are covered in Chapter 53.

Bacterial Infections

Bacterial infections associated with renal disease and the likely mechanisms causing renal dysfunction are shown in Table 52-1 .
Table 52-1

Likely mechanisms causing renal dysfunction in bacterial infections

Organism

Site/infection

Infection localized to kidney

Systemic infection; toxin/inflammation

Ischemia/ hypoperfusion; vasomotor nephropathy

Distant infection; “immunologic/delayed”

Others

 

Neisseria meningitidis

Septicemia

 

++

++

   
 

Chronic meningococcemia

   

+

  

Staphylococcus aureus

Renal abscess

++

     
 

Distant abscess/endocarditis (see Table 52-2 )

   

++

  
 

Sepsis

 

++

++

   
 

Toxic shock

 

++

++

   

Staphylococcus epidermidis

Shunt infection (see Table 52-2 )

   

++

  

Group A Streptococcus

Sepsis

 

++

++

   
 

Toxic shock

 

++

++

   
 

APSGN

   

++

  

Haemophilus influenzae (new biotype)

Brazilian purpuric fever

 

++

++

   

Leptospira interrogans

Leptospirosis, Weil's disease

++

 

++

   

Streptococcus pneumoniae

Sepsis

 

++

++

   
 

Pneumonia

    

+ (HUS)

 

Escherichia coli and Shigella

Sepsis

 

++

++

   
 

Diarrhea

  

++

   
 

Colitis

   

++ (HUS)

  

Salmonella species

Sepsis

 

++

++

+

  
 

Diarrhea

  

++

 

+ (HUS)

 

Vibrio species

Cholera

  

++

   

Klebsiella

Sepsis

 

++

++

   

Yersinia species

Enteritis

   

+

+ (HUS)

 

Campylobacter jejuni

Enteritis

   

+

  

Mycobacteria tuberculosis

Tuberculosis

+

  

+

  

Treponema pallidum

Syphilis

   

+

  

Mycoplasma pneumoniae

Pneumonia

   

+

+ (HUS)

 

Legionella

Pneumonia

+

   

Rhabdomyolysis

 

Rickettsia rickettsii

Rocky mountain spotted fever

+

 

+

   

Coxiella burnetii

Q fever

   

+

  

++, frequent complication of infection; +, uncommon but recognized complication; APSGN, acute post-streptococcal glomerulonephritis; HUS, hemolytic uremic syndrome

Table 52-2

Focal infections causing glomerulonephritis

Site of infection

Organism

 

Infective endocarditis

Coagulase-negative staphylococci

 
 

Staphylococcus aureus

 
 

Pneumococci

 
 

Viridans streptococci

 
 

Enterococci

 
 

Anaerobic streptococci

 
 

Diphtheroids

 
 

Haemophilus influenzae

 
 

Coliforms

 
 

Bacteroides

 
 

Coxiella burnetii

 
 

Legionella

 
 

Candida albicans

 

Shunt infections

Coagulase-negative staphylococci

 
 

S. aureus

 
 

Diphtheroids

 
 

Gram-negative bacilli

 
 

Anaerobes

 

Focal abscess

S. aureus

 
 

Gram-negative bacilli

 

Osteomyelitis

S. aureus/streptococci

 

Pyelonephritis

Coliforms

 

Pneumonia

Streptococcus pneumoniae

 
 

Klebsiella

 
 

S. aureus

 
 

Mycoplasma

 

Otitis media

Pneumococcus/S. aureus

 

Gastrointestinal infection

Yersinia, Campylobacter

 
 

Salmonella, Shigella

 

Systemic Sepsis and Septic Shock

Impaired renal function is a common occurrence in systemic sepsis (1). Depending on the severity of the infection and the organism responsible, the renal involvement may vary from insignificant proteinuria to acute renal failure requiring dialysis. The organisms causing acute renal failure as part of systemic sepsis vary with age and geographic location and also differ in normal and immunocompromised children. In the neonatal period, group B streptococci, coliforms, Staphylococcus aureus, and Listeria monocytogenes are the organisms usually responsible. In older children, Neisseria meningitidis, Streptococcus pneumoniae, and S. aureus account for most of the infections. In people who are immunocompromised, a wide range of bacteria are seen, and, similarly, in tropical countries other pathogens, including Haemophilus influenzae, Salmonella species, and Pseudomonas pseudomallei, must be considered. Where H. influenzae type B vaccine has been introduced, however, the incidence of severe systemic infections due to this organism has shown a sharp fall.

Systemic sepsis usually presents with nonspecific features: fever, tachypnea, tachycardia, and evidence of skin and organ underperfusion. The pathophysiology of renal involvement in systemic sepsis is multifactorial (1, 2). Hypovolemia with diminished renal perfusion is the earliest event and is a consequence of the increased vascular permeability and loss of plasma from the intravascular space. Hypovolemia commonly coexists with depressed myocardial function because of the myocardial depressant effects of endotoxin or other toxins. The renal vasoconstrictor response to diminished circulating volume and reduced cardiac output further reduces glomerular filtration, and oliguria is thus a consistent and early event in severe sepsis (1, 3). A number of vasodilator pathways are activated in sepsis, including Nitric Oxide and the Kinin pathways. This may lead to inappropriate dilatation of vascular beds. Vasodilation of capillary beds leading to warm shock is common in adults with sepsis due to Gram-negative organisms but is less commonly seen in children, in whom intense vasoconstriction is the usual response to sepsis. If renal underperfusion and vasoconstriction are persistent and severe, the reversible prerenal failure is followed by established renal failure with the characteristic features of vasomotor nephropathy or acute tubular necrosis. Other mechanisms of renal damage in systemic sepsis include direct effects of endotoxin and other toxins on the kidney, and release of inflammatory mediators such as tumor necrosis factor (TNF) and other cytokines, arachidonic acid metabolites, and proteolytic enzymes (3). Nitric oxide (NO) is postulated to play a key role in the pathophysiology of renal failure in sepsis. Whether the renal effects of increased NO are beneficial or harmful remains unclear. Trials of selective NO synthetase inhibition did not offer any advantages over saline resuscitation (4). NO in endotoxemia is possibly beneficial because it maintains renal blood flow and glomerular filtration. Activation of coagulation is an important component of the pathophysiology of septic shock and may contribute to renal impairment. Activation of multiple prothrombotic and antifibrinolytic pathways occurs, together with downregulation of antithrombotic mechanisms such as the protein C pathway. Treatment with Activated protein C has been shown to improve outcome of adult septic shock, but has not been confirmed to have benefit in pediatric sepsis, and may carry a risk of bleeding particularly in infants (5).

The renal findings early in septic shock are oliguria, with high urine/plasma urea and creatinine ratios, low urine sodium concentration, and a high urine/plasma osmolarity ratio. Once established, renal failure supervenes, and the urine is of poor quality with low urine/plasma urea and creatinine ratios, elevated urine sodium concentration, and low urine osmolarity. Proteinuria is usually present, and the urine sediment may contain red cells and small numbers of white cells (1).

Management of Acute Renal Failure in Systemic Sepsis

The management of acute renal failure in systemic sepsis depends on early diagnosis and administration of appropriate antibiotics to cover the expected pathogens. In addition, management is directed at improving renal perfusion and oxygenation. Volume replacement with crystalloid or colloid should be undertaken to optimize preload. Central venous pressure or pulmonary wedge pressure monitoring is essential to guide volume replacement in children in severe shock (1, 2). The use of low-dose (2–5 pg/kg/min) dopamine to reduce renal vasoconstriction together with administration of inotropic agents such as dobutamine or epinephrine to improve cardiac output may reverse prerenal failure. Early elective ventilation should be undertaken in patients with severe shock. If oliguria persists despite volume replacement and inotropic therapy, dialysis should be instituted early, because septic and catabolic patients may rapidly develop hyperkalemia and severe electrolyte imbalance.

In most children who develop acute renal failure as part of systemic sepsis or septic shock, the renal failure is of short duration, and recovery can be expected within a few days of achieving cardiovascular stability and eradication of the underlying infection. Occasionally, renal cortical necrosis or infarction of the kidney may result in prolonged or permanent loss of renal function.

Specific Infections Causing the Systemic Sepsis Syndrome

Meningococcus

N. meningitidis continues to be a major cause of systemic sepsis and meningitis in both developed and underdeveloped parts of the world (6). In developed countries, most cases are caused by group B and Y strains, particularly after introduction of meningococcal C vaccination, whereas epidemics of Meningococcus groups A, C and W135 continue to occur in many underdeveloped regions of the world (6, 7). Infants and young adults are most commonly affected, but cases in adolescents and young children are also common. There are two major presentations of meningococcal disease (6): Meningococcal meningitis presents with features indistinguishable from those of other forms of meningitis, including headache, stiff neck, and photophobia. Lumbar puncture is required to identify the causative agent and distinguish this from other forms of meningitis. Despite the acute nature of the illness, the prognosis is good, and most patients with the purely meningitic form of the illness recover without sequelae.

Meningococcemia with purpuric rash and shock is the second and more devastating form of the illness. Affected patients present with nonspecific symptoms of fever, vomiting, abdominal pain, and muscle ache. The diagnosis is only obvious once the characteristic petechial or purpuric rash appears. Patients with a rapidly progressive purpuric rash, hypotension, and evidence of skin and organ underperfusion have a poor prognosis, with a mortality of 10–30%. Adverse prognostic features include hypotension, a low white cell count, absence of meningeal inflammation, thrombocytopenia, and disturbed coagulation indices (8).

Renal failure was seldom reported in early series of patients with meningococcemia, perhaps because most patients died rapidly of uncontrolled septic shock. With advances in intensive care, however, more children are surviving the initial period of profound hemodynamic derangement, and renal failure is more often seen as a major management problem. Approximately 10% of children with fulminant meningococcemia develop renal failure, which usually occurs 24–48 h after the onset of illness (9).

The pathophysiology of meningococcal septicemia involves the activation of cytokines and inflammatory cells by endotoxin (6, 7). Mortality is directly related to both the plasma endotoxin concentration and the intensity of the inflammatory response, as indicated by levels of TNF and other inflammatory markers (10). Patients with meningococcemia have a profound capillary leak leading to severe hypovolemia. Loss of plasma proteins from the intravascular space is probably the major cause of shock (11), but myocardial suppression secondary to IL-6 production is also important (12). Intense vasoconstriction further impairs tissue and organ perfusion, and vasculitis with intravascular thrombosis and consumption of platelets and coagulation factors is also present (6).

Oliguria is invariably present in children with meningococcemia during the initial phase of the disorder. This is prerenal in origin and may respond to volume replacement and inotropic support. If cardiac output cannot be improved and renal underperfusion persists, established renal failure supervenes. Occasionally, cortical necrosis or infarction of the kidneys occurs. Children with meningococcemia should be aggressively managed in a pediatric intensive care unit, with early administration of antibiotics (penicillin or a third-generation cephalosporin), volume replacement, hemodynamic monitoring, and the use of inotropic agents and vasodilators. If oliguria persists despite measures to improve cardiac output, elective ventilation and dialysis should be instituted early (6, 7). Because activation of coagulation pathways occurs, severe acquired protein-C deficiency may result and is usually associated with substantial mortality (13). Protein C is a natural anticoagulant which also has important anti-inflammatory activity. Despite evidence for impaired function of the activated protein C pathway in meningococcal diseases (14), and adult trials suggesting benefit of activated protein C administration in Septic shock (PROWESS trial) (15), pediatric trials of activated protein C showed no clear benefit, and were associated with increased risk of intracranial bleeding in very young infants (5). The role of aPC therapy in pediatric sepsis remains unclear. Most patients who survive the initial 24–48 h of the illness and regain hemodynamic stability will ultimately recover renal function even if dialysis is required for several weeks.

The least common presentation of meningococcal sepsis is chronic meningococcemia. Patients with this form of the illness present insidiously with a vasculitic rash, arthritis, and evidence of multiorgan involvement. The features may overlap those of Henoch-Schonlein purpura or subacute bacterial endocarditis (SBE), and the diagnosis must be considered in patients presenting with fever, arthritis, and vasculitic rash, often accompanied by proteinuria or hematuria. Response to antibiotic treatment is good, but some patients may have persistent symptoms for many days resulting from an immune-complex vasculitis.

Staphylococcus Aureus

Staphylococcal infections may affect the kidneys by direct focal invasion during staphylococcal septicemia, forming a renal abscess; by causing staphylococcal bacteremia; or by toxin-mediated mechanisms, as in the staphylococcal toxic shock syndrome.

Staphylococcal Abscess. Staphylococcal renal abscess presents with fever, loin pain and tenderness, and abnormal urine sediment, as do abscesses caused by other organisms (16). The illness often follows either septicemia or pyelonephritis. The diagnosis is usually considered only when a patient with clinical pyelonephritis shows an inadequate response to antibiotic treatment. The diagnosis is confirmed by ultrasonography or computed tomographic scan, which shows swelling of the kidney and intrarenal collections of fluid. Antibiotic therapy alone may result in cure, but if the patient remains unwell with evidence of persistent inflammation despite use of appropriate antibiotics, surgical intervention may be required. Percutaneous drainage under ultrasonographic or computed tomographic scan guidance is often effective and may avoid the need for a more direct surgical approach (16, 17).

Staphylococcal Toxic Shock Syndrome. The staphylococcal toxic shock syndrome is a systemic illness characterized by fever, shock, erythematous rash, diarrhea, confusion, and renal failure. The disorder was first described by Todd et al. in 1978 in a series of seven children (18). During the 1980s, thousands of cases were reported in the United States. Most cases were in menstruating women, in associated with tampon use. Although most cases worldwide are seen in women and are associated with menstruation, children of both sexes and of all ages are affected (19).

The illness usually begins suddenly with high fever, diarrhea, and hypotension, together with a diffuse erythroderma (20). Mucous membrane involvement with hyperemia and ulceration of the lips and oral mucosa or vaginal mucosa, strawberry tongue, and conjunctival injection are usually seen. Desquamation of the rash occurs in the convalescent phase of the illness. Confusion is often present in the early stages of the illness and may progress to coma in severe cases. Multiple organ failure with evidence of impaired renal function, elevated levels of hepatic transaminases, thrombocytopenia, elevated CPK and disseminated intravascular coagulation (DIC) is often seen.

According to CDC criteria, the diagnosis is made on the basis of the clinical features of fever, rash, hypotension, and subsequent desquamation along with deranged function of three or more of the following organ systems: gastrointestinal (GI), mucous membranes, renal, hepatic, hematologic, central nervous system, and muscle. Other disorders causing a similar picture, such as Rocky Mountain spotted fever, leptospirosis, measles, and streptococcal infection, must be excluded.

The staphylococcal toxic shock syndrome is now known to be due to infection or colonization with strains of S. aureus that produce one or more protein exotoxins (21). Most cases in adults are associated with toxic shock toxin I; in children, many of the isolates associated with the syndrome produce other enterotoxins (A to F). The staphylococcal enterotoxins appear to induce disease by acting as superantigens (22), which activate T cells bearing specific V beta regions of the T-cell receptor; this causes proliferation and cytokine release (23). The systemic illness and toxicity are believed to result largely from an intense inflammatory response induced by the toxin. The site of toxin production is often a trivial focus of infection or simple colonization, and bacteremia is rarely observed.

Renal failure in toxic shock syndrome is usually caused by shock and renal hypoperfusion. In the early stages of the illness, oliguria and renal impairment are usually prerenal and respond to treatment of shock and measures to improve perfusion. In severe cases and in patients in whom treatment is delayed, acute renal failure develops as a consequence of prolonged renal underperfusion, and dialysis may be required. In addition to underperfusion, direct effects of the toxin or inflammatory mediators may also contribute to the renal damage. Recovery of renal function usually occurs, but in severe cases with cortical necrosis or intense renal vasculitis, prolonged dialysis may be required.

The management of staphylococcal toxic shock syndrome depends on early diagnosis and aggressive cardiovascular support with volume replacement, inotropic support, and, in severe cases, elective ventilation. If oliguria persists despite optimization of intravascular volume and administration of inotropic agents, dialysis should be commenced early (20).

Anti-staphylococcal antibiotics should be started as soon as the diagnosis is suspected and the site of infection identified. Initial empiric antimicrobial therapy should include an anti-staphylococcal antibiotic effective against betalactamase-resistant organisms and a protein synthesis-inhibiting antibiotic such as clindamycin to stop further toxin production (24). If there is a focus of infection such as a vaginal tampon, surgical wound, or infected sinuses, the site should be drained early to prevent continued toxin release into the circulation. The intravenous administration of immune globulins may be considered when infection is refractory to several hours of aggressive therapy, an undrainable focus is present, or persistent oliguria with pulmonary edema occurs (24). With aggressive intensive care, most affected patients survive, and renal recovery is usual, even in patients who have had severe shock and multiorgan failure. Relapses and recurrences of staphylococcal toxic shock syndrome occur in a proportion of affected patients because immune responses to the toxin are ineffective in some individuals.

Panton Valentine Leucocidin (PVL) producing staphylococcal infection: In recent years there have been increasing reports of severe staphylococcal disease, associated with shock and multiorgan failure, caused by strains of staphylococci producing the PVL toxin. Panton-Valentine Leukocidin (PVL) is a phage-encoded toxin, which profoundly impairs the host response due to its toxic effect on leucocytes (see review (25)). PVL producing strains are associated with tissue necrosis and increased propensity to cause abscesses in lung, bone, joint, and soft tissue infections. Perinephric abscesses have been reported (26). There are increasing numbers of children and adults admitted with fulminant sepsis, and shock due to PVL producing strains, and renal failure is a significant component of the multiorgan failure. In addition to intensive care support, antibiotic treatment of PVL strains should include antibiotics which reduce toxin production, such as clindamycin, linezolid or rifampicin, as well as vancomycin if the strain is resistant to methicillin. Beta-lactam antibiotics should be avoided, as there is some data to suggest that PVL toxin production can increased by these antibiotics under some conditions (27). Immunoglobulin infusion may also be of benefit. Aggressive surgical drainage of all collections requires close consultation with orthopedic and surgical teams.

Streptococcus Pyogenes

The group A streptococci (GAS) are a major worldwide cause of renal disease, usually as poststreptococcal nephritis. However, in addition to this post-infection immunologically mediated disorder, in recent years there have been increasing reports of GAS causing acute renal failure as part of an invasive infection with many features of the staphylococcal toxic shock syndrome (28).

Acute Poststreptococcal Glomerulonephritis. Acute poststreptococcal GN (APSGN) is a delayed complication of pharyngeal infection or impetigo with certain nephritogenic strains of GAS. Different strains can be serotyped according to the antigenic properties of the M protein found in the outer portion of the bacterial wall. APSGN after pharyngeal infection is most commonly associated with serotype M12. In contrast, in APSGN after impetigo, serotype M49 is most commonly identified (29). On occasions, other serotypes and non-typeable strains have been described as causing GN.

The pathology and pathogenesis of the disorder is discussed in detail in Chapter 30. APSGN has a worldwide distribution. Epidemiologic differences are observed between pharyngitis-associated and impetigo-associated streptococcal infections. Pharyngitis-associated APSGN is most common during school age and has an unexplained male/female ratio of 2:1. It occurs more often in the cooler months, and familial occurrences are commonly described. The latent period is 1–2 weeks, in notable contrast to impetigo-associated cases, which have a latent period of 2–6 weeks. In many developing countries, children have chronic skin infections, and it may be difficult to establish the latent period with accuracy. Impetigo-associated cases are more common in the warmer months, sex distribution is equal, and children tend to be younger. Introduction of a nephritogenic strain into a family often results in the occurrence of several cases within that family, and in some cases, attack rates of up to 20% have been described (30). The incidence is linked to poor socioeconomic conditions.

Renal involvement in APSGN can be mild, and in many patients, the disease may not be manifested clinically. Studies of epidemics with nephritogenic strains of streptococci have shown that up to 50% of those infected had subclinical evidence of renal disease (30, 31). In a typical case a sudden onset of facial or generalized edema occurs. Hypertension is usually modest but is severe in 5% of cases, and occasionally may lead to encephalopathy or left ventricular failure. The urine is smoky or tea colored in 30–50% of cases. Pallor, headache, backache, lethargy, malaise, anorexia, and weakness are all common nonspecific features.

The urine volume is decreased. Proteinuria is present (up to 100 mg/dL), and microscopy shows white cells, red cells, and granular and hyaline casts. Urea, electrolyte, and creatinine levels are normal in subclinical cases but show features of acute renal failure in severe cases. It may be possible to culture GAS from the skin or the throat in some patients. Other evidence of infection with a GAS can be obtained through the antistreptolysin-O titer (ASOT), which is increased in 60–80% of cases. Early antibiotic treatment can reduce the proportion of cases with elevated ASOT to 30%. Anti-deoxyribonuclease B and anti-hyaluronidase testing has been shown to be of more value than ASOT in confirming group A streptococcal infection in impetigo-associated cases. Measurement of anti-M protein antibodies is of more value for epidemiologic purposes than for the diagnosis of individual cases (31). Decreased C3 and total hemolytic complement levels are found in 90% of cases during the first 2 weeks of illness and return to normal after 4–6 weeks.

Penicillin should be given to eradicate the GAS organisms. Erythromycin, clindamycin, or a first-generation cephalosporin can be given to patients allergic to penicillin. Antibiotic treatment probably has no influence on the course of renal disease but will prevent the spread of a nephritogenic strain (32). Close contacts and family members who are culture-positive for GAS should also be given penicillin, although antibiotic treatment is not always effective in eliminating secondary cases. Recurrent episodes are rare, and immunity to the particular nephritogenic strain that caused the disease is probably lifelong. Antibiotic prophylaxis is therefore unnecessary.

Most studies suggest that the prognosis for children with APSGN is good, with more than 90% making a complete recovery. However, 10% of cases may have a prolonged and more serious course with long-term chronic renal failure (33).

Other Streptococci. APSGN has also been described after outbreaks of group C Streptococcus infection (34). This has occurred after consumption of unpasteurized milk from cattle with mastitis. Patients developed pharyngitis followed by APSGN. Endostreptosin was found in the cytoplasm of these group C strains, and during the course of the illness, patients developed anti-endostreptosin antibodies. This antigen has been postulated to be the nephritogenic component of GAS.

In addition, strains of group G streptococci have been implicated in occasional cases of APSGN (35). Isolates possessed the type M12 protein antigen identical to the nephritogenic type M12 antigen of some group A streptococcal strains.

Streptococcal Toxic Shock Syndrome and Invasive Group A Streptococcal Infection. Since 1988, there have been several reports of an illness with many similarities to the staphylococcal toxic shock syndrome, occurring in both children (36) and adults, associated with invasive group A streptococcal disease (32, 37, 38). Patients with this syndrome present acutely with high fever, erythematous rash, mucous membrane involvement, hypotension, and multiorgan failure. Unlike staphylococcal toxic shock syndrome, in which the focus of infection is usually trivial and bacteremia is seldom seen, the streptococcal toxic shock syndrome is usually associated with bacteremia or a serious focus of infection such as septic arthritis, myositis, or osteomyelitis (36, 38). Laboratory findings of anemia, neutrophil leukocytosis, thrombocytopenia, and DIC are often present, together with impaired renal function, hepatic derangement, and acidosis. Acute renal failure requiring dialysis occurs in a significant proportion of cases.

It is not clear why there are increasing numbers of cases with invasive disease caused by GAS, nor why there has been an emergence of streptococcal toxic shock syndrome, and indeed a similar syndrome caused by some pseudomonas and klebsiella strains. The most common antecedent of invasive GAS disease is varicella infection, with the streptococcal infection developing after the initial vesicular phase of the disease is subsiding. Strains causing toxic shock syndrome and invasive disease appear to differ from common isolates of GAS in producing large amounts of pyrogenic toxins that may have superantigen-like activity. Another important mechanism is the production by invasive GAS of an IL8 protease. IL8 serves as a molecular bridge between receptors on neutrophils and the vascular endothelium. Cleavage of this protein prevents neutrophil attachment to the endothelium, and results in uncontrolled spread of the bacteria through the tissues (39). In severe cases necrotizing fasciitis occurs with extensive destruction of the subcutaneous tissues, and is often associated with multiorgan failure. The pathophysiology of streptococcal toxic shock syndrome and that of invasive disease is similar in that superantigen toxins that induce release of cytokines and other inflammatory mediators play a role in both conditions. However GAS toxic shock is usually more severe, carries a higher mortality, and is more often associated with focal collections or necrotizing fasciitis.

Treatment of streptococcal toxic shock syndrome depends on the administration of appropriate antibiotics, aggressive circulatory support, and treatment of any multiorgan failure. Surgical intervention to drain the infective focus in muscle, bone, joint, or body cavities is often required. Antibiotic therapy with beta-lactams should be supplemented by treatment with a protein synthesis-inhibiting antibiotic, such as clindamycin, and it is suggested that this limits new toxin production (40, 41).

A number of new therapies are in development. Firstly, pooled intravenous immunoglobulins are now in widespread use in the treatment of toxic shock, particularly when caused by streptococcus (42, 43).

The role of steroids remains unclear, with their hemodynamic benefit set against the detrimental effects of hyperglycemia secondary to gluconeogenesis. (44). The benefit of insulin therapy to control hyperglycemia is unclear. A recent study in adults found that intensive insulin therapy increased the risk of serious adverse events (45). In contrast to adult patients, in children with severe sepsis, the use of activated protein C (Drotrecogin) cannot be recommended, as in a multicenter trial, fatality was increased in the treatment group (5). Recovery of renal function occurs in patients who respond to treatment of shock and the eradication of the infection.

Leptospira

Leptospirosis is an acute generalized infectious disease caused by spirochetes of the genus Leptospira (46). It is primarily a disease of wild and domestic animals, and humans are infected only occasionally through contact with animals. Most human cases occur in summer or autumn and are associated with exposure to leptospira-contaminated water or soil during recreational activities such as swimming or camping. In adolescents and adults, occupational exposure through farming or other contact with animals is the route of infection.

The spirochete penetrates intact mucous membranes or abraded skin and disseminates to all parts of the body, including the cerebrospinal fluid (CSF). Although leptospires do not contain classic endotoxins, the pathophysiology of the disorder has many similarities to that of endotoxemia. In severe cases, jaundice occurs because of hepatocellular dysfunction and cholestasis. Renal functional abnormalities may be profound and out of proportion to the histologic changes in the kidney (47). Renal involvement is predominantly a result of tubular damage, and spirochetes are commonly seen in the tubular lesions. The inflammatory changes in the kidney may result from either a direct toxic effect of the organism or immune-complex nephritis. However, hypovolemia, hypotension, and reduced cardiac output caused by myocarditis may contribute to the development of renal failure. In severe cases, a hemorrhagic disorder caused by widespread vasculitis and capillary injury also occurs (47, 48).

The clinical manifestations of leptospirosis are variable. Of affected patients, 90% have the milder anicteric form of the disorder, and only 5–10% have severe leptospirosis with jaundice. The illness may follow a biphasic course. After an incubation period of 7–12 days, a nonspecific flu-like illness lasting 4–7 days occurs, associated with septicemic spread of the spirochete. The fever then subsides, only to recur for the second, “immune,” phase of the illness. During this phase, the fever is low grade and there may be headache and delirium caused by meningeal involvement, as well as intense muscular aching. Nausea and vomiting are common. Examination usually reveals conjunctival suffusion, erythematous rash, lymphadenopathy, and meningism.

The severe form of the disease (Weil's disease) presents with fever, impaired renal and hepatic function, hemorrhage, vascular collapse, and altered consciousness. In one series the most common organs involved were the liver (71%) and kidney (63%). Cardiovascular (31%), pulmonary (26%), neurologic (5%), and hematologic (21%) involvements were less common (49). Vasculitis, thrombocytopenia, and uremia are considered important factors in the pathogenesis of hemorrhagic disturbances and the main cause of death in severe leptospirosis (50). Urinalysis results are abnormal during the leptospiremic phase with proteinuria, hematuria, and casts. Uremia usually appears in the second week, and acute renal failure may develop once cardiovascular collapse and DIC are present (48).

The clinical features of leptospirosis overlap with those of several other acute infectious diseases, including Rocky Mountain spotted fever, toxic shock syndrome, and streptococcal sepsis. The diagnosis of leptospirosis should be considered in febrile patients with evidence of renal, hepatic, and mucous membrane changes and rash, particularly if a history of exposure to fresh water is found. Diagnosis can be confirmed by isolation of the spirochetes from blood or CSF in the first 10 days of the illness or from urine in the second week (48). The organism may be seen in biopsy specimens of the kidney or skin or in the CSF by dark-field microscopy or silver staining. Serologic tests to detect leptospirosis are now sensitive and considerably aid the diagnosis. Immunoglobulin M (IgM) antibody may be detected as early as 6–10 days into the illness, and antibody titers rise progressively over the next 2–4 weeks. Some patients remain seronegative, and negative serologic test results do not completely exclude the diagnosis. In one series levels of IgM and IgG anticardiolipin concentrations were significantly increased in leptospirosis patients with acute renal failure (50). Leptospirosis is treated with intravenous penicillin or other beta-lactam antibiotics. The severity of leptospirosis is reduced by antibiotic treatment, even if started late in the course of the illness (51). Supportive treatment with volume replacement to correct hypovolemia, administration of inotropes, and correction of coagulopathy is essential in severe cases. Dialysis may be required in severe cases and may be needed for prolonged periods until recovery occurs.

Streptococcus Pneumoniae

Infection with S. pneumoniae is one of the most common infections in humans and causes a wide spectrum of disease, including pneumonia, otitis media, sinusitis, septicemia, and meningitis. Despite the prevalence of the organism, significant renal involvement is relatively rare but is seen in two situations: pneumococcal septicemia in asplenic individuals or in those with other immune deficiencies presents with fulminant septic shock in which renal failure may occur as part of a multisystem derangement. The mortality from pneumococcal sepsis in asplenic patients is high, even with early antibiotic treatment and intensive support.

The second nephrologi syndrome associated with S. pneumoniae is a rare form of HUS. In 1955, Gasser and colleagues described HUS as a clinical entity in children, and they included two infants with pneumonia among the five patients they described (52). HUS associated with pneumococcal infection is induced by the enzyme neuraminidase released from S. pneumoniae (53, 54). Thomsen-Friedenrich antigen (T antigen) is present on the surface of red blood cells, platelets, and glomerular capillary endothelia against which antibodies are present in normal serum. Neuraminidase causes desialation of red blood cells, and possibly other blood cells and endothelium, by the removal of terminal neuraminic acid, which leads to unmasking of the T antigen. The resultant widespread agglutination of blood cells causes intravascular obstruction, hemolysis, thrombocytopenia, and renal failure. Results of the direct Coombs test are frequently positive, either from bound anti-T IgM or from anti-T antibodies. The diagnosis of Thomsen-Friedenrich antibody-induced HUS should be suspected in patients with acute renal failure, thrombocytopenia and hemolysis after an episode of pneumonia or bacteremia caused by S. pneumoniae. Fragmented red blood cells will usually be present on blood film.

Association with S. pneumoniae is defined by culture of pneumococci from a normally sterile site within a week before or after onset of signs of HUS. Clues to a pneumococcal cause, in addition to culture results, include severe clinical disease, especially pneumonia, empyema, pleural effusion, or meningitis; hemolytic anemia without a reticulocyte response; positive results on a direct Coombs test; and difficulties in ABO crossmatching or a positive minor crossmatch incompatibility (55). However, when renal disease is seen in the context of severe pneumococcal infection, it is important to maintain a broad diagnostic perspective, because the occurrence of acute tubular necrosis due to septic shock and DIC is well described (56, 57).

Therapy for this syndrome should be with supportive treatment and antibiotics (usually a third generation cephalosporin); dialysis may be required if renal failure occurs. Because normal serum contains antibodies against the Thomsen-Friedenrich antigen, blood transfusion should be undertaken with washed red blood cells resuspended in albumin rather than plasma (53, 54). Exchange transfusion and plasmapheresis have been used in some patients, with the rationale that these procedures may improve outcome by eliminating circulating neuraminidase (53, 57, 58). Intravenous IgG has been used in a patient and was shown to neutralize neuraminidase present in the patient’s serum (59).

In comparison to patients with the more common diarrhea-associated HUS, S. pneumoniae-induced HUS patients have a more severe renal disease. They are more likely to require dialysis. Their long-term outcome maybe affected by the severity of the invasive streptococcal disease itself, and a significant proportion of surviving patients (30–70%) develop end-stage renal failure (60, 61). A recent review of UK cases found an eightfold increase in early mortality as compared to diarrhoea-induced HUS (62).

Gastrointestinal Infections (Escherichia coli, Salmonella, Campylobacter, Yersinia, Shigella, Vibrio cholerae)

The diarrheal diseases caused by Escherichia coli, Salmonella, Shigella, Campylobacter, vibrios, and Yersinia remain important and common bacterial infections of humans. Although improvements in hygiene and living conditions have reduced the incidence of bacterial gastroenteritis in developed countries, these infections remain common in underdeveloped areas of the world, and outbreaks and epidemics continue to occur in both developed and underdeveloped countries. Renal involvement in the enteric infections may result from any of four possible mechanisms.

Severe Diarrhea and Dehydration

Regardless of the causative organism, diarrhea results in hypovolemia, abnormalities of plasma electrolyte composition, and renal underperfusion. If severe dehydration occurs and is persistent, oliguria from prerenal failure is followed by vasomotor nephropathy and established renal failure.

Systemic Sepsis and Endotoxemia

E. coli, Shigella, and Salmonella (particularly Salmonella typhi) may invade the bloodstream and induce septicemia or septic shock. Acute renal failure is commonly seen in infants with E. coli sepsis but is also reported with Klebsiella, Salmonella, and Shigella infections. Its pathophysiology and treatment were discussed previously.

Enteric Pathogen-Associated Nephritis

Enteric infections with E. coli, Yersinia, Campylobacter, and Salmonella have been associated with several different forms of GN, including membranoproliferative GN (MPGN), interstitial nephritis, diffuse proliferative GN, and IgA nephropathy (63, 64, 65).

In typhoid fever, GN ranging from mild asymptomatic proteinuria and hematuria to acute renal failure may occur (64, 66, 67, 68). Renal biopsy findings show focal proliferation of mesangial cells, hypertrophy of endothelial cells, and congested capillary lumina. Immunofluorescent studies show IgM, IgG, and C3 deposition in the glomeruli, with Salmonella antigens detected within the granular deposits in the mesangial areas. In the IgA nephropathy after typhoid fever, Salmonella vi antigens have been demonstrated within the glomeruli.

Yersinia infection has been reported as a precipitant of GN in several studies (65, 69). Transient proteinuria and hematuria are found in 24% of patients with acute yersinia infection, and elevated creatinine levels in 10%. Renal biopsy reveals mild mesangial GN or IgA nephropathy. Yersinia antigens, immunoglobulin, and complement have been detected in the glomeruli. Yersinia pseudotuberculosis is well recognized as one of the causes of acute tubulointerstitial nephritis causing acute renal failure, especially in children; patients have histories of drinking untreated water in endemic areas (70, 71, 72). The illness begins with the sudden onset of high fever, skin rash, and GI symptoms. Later in the course, periungual desquamation develops, mimicking Kawasaki disease. Elevated erythrocyte sedimentation rate, C-reactive protein level, and thrombocytosis are noticeable, and mild degrees of proteinuria, glycosuria, and sterile pyuria are common. Acute renal failure, which typically develops 1–3 weeks after the onset of fever, follows a benign course with complete recovery. Renal biopsy mainly reveals findings of acute tubulointerstitial nephritis. Antibiotic therapy, although recommended, does not alter the clinical course, but reduces the fecal excretion of the organism (73, 74).

Enteric Pathogen-Induced Hemolytic Uremic Syndrome

HUS is characterized by three distinct clinical signs: acute renal failure, thrombocytopenia, and microangiopathic hemolytic anemia. It was first described in 1955 and was associated with infection by Shiga toxin-producing Shigella dysenteriae. A major breakthrough in the search for the cause of HUS occurred in the 1980s when Karmali et al. reported that 11 of 15 children with diarrhea-associated HUS had evidence of infection with a strain of E. coli that produced a toxin active on Vero cells (75). In diarrhea-associated HUS in the United States and most of Europe, E. coli 0157:H7 is the most important of these strains. E. coli 0157:H7 occurs naturally in the GI tract of cattle and other animals, and humans become infected through contaminated food products. Most outbreaks have been associated with consumption of undercooked meat, but unpasteurized milk and cider, drinking water, and poorly chlorinated water for recreational use have also been implicated as vehicles for bacterial spread. HUS is discussed in detail in Chapter 67.

Mycobacterium Tuberculosis

The global epidemic of Mycobacterium tuberculosis is growing. Several factors have contributed to this increase, including the emergence of the human immunodeficiency virus (HIV) infection epidemic, large influxes of immigrants from countries in which tuberculosis (TB) is common, the emergence of multiple-drug-resistant M. tuberculosis, and breakdown of the health services for effective control of TB in various countries. It is generally estimated that, overall, one-third of the world's population is currently infected with the TB bacillus. There are more than 8 million cases of TB, which result in the death of approximately 2 million people each year. Furthermore, 5–10% of people who are infected with the TB bacillus develop TB disease or become infectious at some time during their lives (76, 77). After respiratory illness in children, mycobacteria are widely distributed to many organs of the body during the lymphohematogenous phase of childhood TB (78). Tubercle bacilli can be recovered from the urine in many cases of miliary TB. Hematogenously-spread tuberculomata develop in the glomeruli, which results in caseating, sloughing lesions that discharge bacilli into the tubules. In most cases, the renal lesions are asymptomatic and manifest as mycobacteria in the urine or as sterile pyuria.

Tuberculomata in the cortex may calcify and cavitate or may rupture into the pelvis, discharging infective organisms into the tubules, urethra, and bladder. Dysuria, loin pain, hematuria, and pyuria are the presenting features of this complication, but in many cases, the renal involvement is asymptomatic, even when radiologic and pathologic abnormalities are very extensive. Continuing tuberculous bacilluria may cause cystitis with urinary frequency and, in late cases, a contracted bladder (79). The intravenous urogram is abnormal in most cases. Early findings are pyelonephritis with calyceal blunting and calyceal-interstitial reflux. Later, papillary cavities may be seen, indicating papillary necrosis. Ureteric strictures, focal calcification, hydronephrosis, and cavitation may also be seen. Renal function is usually well preserved, and hypertension is uncommon. In some cases, either the infection itself or reactions to the chemotherapeutic agents may result in renal failure with evidence of an interstitial nephritis (79, 80, 81).

Classic symptomatic renal TB is a late and uncommon complication in children, rarely occurring less than 4 or 5 years after the primary infection, and therefore is most commonly diagnosed after adolescence (78, 80). Adult studies have shown that 26–75% of renal TB coexists with active pulmonary TB and 6–10% of screened sputum-positive pulmonary TB patients have renal involvement.

The diagnosis is established by isolation of mycobacteria from the urine or by the presence of the characteristic clinical and radiographic features in a child with current or previous TB. Renal TB is treated with drug regimens similar to those used for other forms of TB, with isoniazid, rifampicin, pyrazinamide and ethambutol administered initially for 2 months, and isoniazid and rifampicin then continued for a further 7–10 months. Late scarring and urinary obstruction may occur in cases with extensive renal involvement, and such patients should be followed by ultrasonography or intravenous urogram.

Mycobacteria, both M. tuberculosis and atypical mycobacteria, have also emerged as important causes of opportunistic infection in immunocompromised patients undergoing dialysis and in patients undergoing renal transplantation. The possibility of mycobacterial disease must be considered in patients with fever of unknown origin or unexplained disease in the lungs or other organs. Results of the Mantoux test are often negative, and diagnosis depends on maintaining a high index of suspicion and isolating the organism from the infected site.

Treponema Pallidum

Renal involvement has been well documented in both congenital and acquired syphilis, with an estimated occurrence of 0.3% in patients with secondary syphilis and up to 5% in those with congenital syphilis (82, 83). The most common manifestation of renal disease in congenital syphilis is the nephrotic syndrome, with proteinuria, hypoalbuminemia, and edema. In some patients, hematuria, uremia, and hypertension may be seen. The renal disease is usually associated with other manifestations of congenital syphilis, including hepatosplenomegaly, rash, and mucous membrane findings.

Nephritis in congenital syphilis is usually associated with evidence of complement activation, with depressed levels of Clq, C4, C3, and C5. Histologic findings are a diffuse proliferative GN or a membranous nephropathy. The interstitium shows a cellular infiltrate of polymorphonuclear and mononuclear cells (84). Immunofluorescent microscopy reveals diffuse granular deposits of IgG and C3 along the glomerular basement membrane (GBM). Mesangial deposits may also contain IgM. On electron microscopy, scattered subepithelial electron-dense deposits are seen, with fusion of epithelial cell foot processes (84).

Good evidence exists that renal disease is due to an immunologically mediated reaction to treponemal antigens. Antibodies reactive against treponemal antigens can be eluted from the glomerular deposits, and treponemal antigens are present in the immune deposits. Treatment of both congenital and acquired syphilis with antibiotics results in rapid improvement in the renal manifestations (82, 84).

Mycoplasma Pneumoniae

Renal involvement is surprisingly rare in Mycoplasma pneumoniae infection considering the prevalence of this organism and its propensity to trigger immunologically mediated diseases such as erythema multiforme, arthritis, and hemolysis. Acute nephritis associated with Mycoplasma infection may occur 10–40 days after the respiratory tract infection (85, 86). Renal histopathologic findings include type 1 MPGN, proliferative endocapillary GN, and minimal change disease (87). Antibiotic treatment of the infection does not appear to affect the renal disease, which is self-limited in most cases (85, 86).

Legionnaires’ Disease

Since its recognition in 1976, Legionnaires’ disease, caused by Legionella pneumophila, has emerged as an important cause of pneumonia. The disease most commonly affects the elderly but has been reported in both normal and immunocompromised children (97, 98). Renal dysfunction occurs in a minority of patients (98). Patients who develop renal impairment present with oliguria and rising urea and creatinine levels. They are usually severely ill, with bilateral pulmonary infiltrates, fever, and leukocytosis. Shock may be present, and the renal impairment has been associated with acute rhabdomyolysis with high levels of creatine phosphokinase and myoglobinuria. Renal histologic examination usually shows a tubulointerstitial nephritis or acute tubular necrosis (98, 99). The pathogenesis of the renal impairment is uncertain, but the organism has been detected within the kidney on electron microscopy and immunofluorescent studies, which suggests a direct toxic effect. Myoglobinuria and decreased perfusion may also be contributing factors, however. Mortality has been high in reported cases of Legionnaires’ disease complicated by renal failure. Treatment is based on dialysis, intensive care, and antimicrobial therapy with erythromycin (98). Steroid therapy may be effective for tubulointerstitial nephritis (99).

Rickettsial Diseases

The rickettsial diseases are caused by a family of microorganisms that have characteristics common to both bacteria and viruses and that cause acute febrile illnesses associated with widespread vasculitis. With the exception of Q fever, all are associated with erythematous rashes. There are four groups of rickettsial diseases:
  1. 1.

    The typhus group includes louse-borne and murine typhus, spread by lice and fleas, respectively.

     
  2. 2.

    The spotted fever group includes Rocky Mountain spotted fever, tick typhus and related Mediterranean spotted fever and rickettsial pox, which are spread by ticks and mites, with rodents as the natural reservoir.

     
  3. 3.

    Scrub typhus, which is spread by mites.

     
  4. 4.

    Q fever, which is spread by inhalation of infected particles from infected animals.

     
Rickettsial diseases have a worldwide distribution and vary widely in severity, from self-limited infections to fulminant and often fatal illnesses (88). In view of the widespread vasculitis associated with these infections, subclinical renal involvement probably occurs in many of the rickettsial diseases. However, in Rocky Mountain spotted fever, tick typhus, and Q fever, the renal involvement may be an important component of the illness.

Rocky Mountain Spotted Fever

Rocky Mountain spotted fever is the most severe of the rickettsial diseases (89, 90). The onset occurs 2–8 days after the bite of an infected tick. High fever develops initially, followed by the pathognomonic rash, which occurs between the second and sixth days of the illness. The rash initially consists of small erythematous macules, but later these become maculopapular and petechial, and in untreated patients, confluent hemorrhagic areas may be seen. The rash first appears at the periphery and spreads up the trunk. Involvement of the palms and soles is a characteristic feature (88).

Headache, restlessness, meningism, and confusion may occur together with other neurologic signs. Cardiac involvement with congestive heart failure and arrhythmia are common. Pulmonary involvement occurs in 10–40% of cases. Infection is associated with an initial leucopenia, followed by neutrophil leukocytosis. Thrombocytopenia occurs in most cases.

Histopathologically, the predominant lesions are in the vascular system (91). Rickettsiae multiply in the endothelial cells, which results in focal areas of endothelial cell proliferation, perivascular mononuclear cell infiltration, thrombosis, and leakage of red cells into the tissues. The renal lesions involve both blood vessels and interstitium, and acute tubular necrosis may occur. Acute GN with immune-complex deposition has been reported (92), but in most cases the pathology appears to be a direct consequence of the invading organism on the renal vasculature (90, 93).

Renal dysfunction is an important complication of Rocky Mountain spotted fever. Elevation of urea and creatinine levels occurs in a significant proportion of cases, and acidosis is common. Prerenal renal failure caused by hypovolemia and impaired cardiac function may respond to volume replacement and inotropic support, but acute renal failure may subsequently occur, necessitating dialysis.

Rocky Mountain spotted fever is diagnosed by the characteristic clinical picture, the exclusion of disorders with similar manifestations (e.g., measles, meningococcal disease, and leptospirosis), and detection of specific antibodies in convalescence. Culture of Rickettsia rickettsii, immunofluorescent staining, and polymerase chain reaction (PCR) testing of blood and skin biopsy specimens are available only in reference laboratories. Antibiotics should be administered in suspected cases without awaiting confirmation of the diagnosis (93). Doxycycline is the drug of choice for children of any age. Chloramphenicol is also effective (94). Intensive support of shock and multiorgan failure may be required in severe cases, and peritoneal dialysis or hemodialysis may be required until renal function returns. Before the advent of specific therapy, mortality was 25%. Today the overall mortality in the United States is still 5–7%. Death predominantly occurs in cases in which the diagnosis is delayed.

Q Fever

Q fever is caused by Coxiella burnetii and has a worldwide distribution, with the animal reservoir being cattle, sheep, and goats. Human infection follows inhalation of infected particles from the environment. The clinical manifestations range from an acute self-limited febrile illness with atypical pneumonia to involvement of specific organs that causes endocarditis, hepatitis, osteomyelitis, and central nervous system disease (95).

Proliferative GN may be associated with either Q fever endocarditis, rhabdomyolysis or a chronic infection elsewhere in the body (96). Renal manifestations range from asymptomatic proteinuria and hematuria to acute renal failure, hypertension, and nephrotic syndrome. Renal histologic findings are those of a diffuse proliferative GN, focal segmental GN, or mesangial GN. Immunofluorescent studies reveal diffuse glomerular deposits of IgM in the mesangium, together with C3 and fibrin. C. burnetii antigen has not been identified within the renal lesions.

Treatment of the underlying infection may result in remission of the renal disease, but prolonged treatment may be required for endocarditis. Tetracycline has been used in conjunction with rifampicin, co-trimoxazole, or a fluoroquinolone.

Intravascular and Focal Infections

Nephritis has been reported in association with the presence of a wide range of microorganisms that cause chronic or persistent infection (Table 52-2 ) (63, 100). It is likely that any infectious agent that releases foreign antigens into the circulation, including those of very low virulence, can cause renal injury either by deposition of foreign antigens in the kidney or by the formation of immune complexes in the circulation, which are then deposited within the kidney. Nephritis is most commonly seen in association with intravascular infections such as SBE or infected ventriculoatrial shunts, but it is also seen after focal extravascular infections; ear, nose, and throat infections; and abscesses.

Bacterial Endocarditis

Renal involvement is one of the diagnostic features of bacterial endocarditis. Virtually all organisms that cause endocarditis also produce renal involvement (Table 52-2 ). Although endocarditis caused by bacteria is the most common and is readily diagnosed by blood culture (100), unusual but important causes of culture-negative endocarditis include Q fever (101) and Legionella infection (102). In the immunocompromised individual, opportunistic pathogens such as fungi and mycobacteria are important causes.

The usual renal manifestations of SBE are asymptomatic proteinuria, hematuria, and pyuria. Loin pain, hypertension, nephrotic syndrome, and renal failure may occur in more severe cases.

The renal lesions occurring in endocarditis are variable, and focal embolic and immune-complex-mediated features may coexist (100, 103, 104). Embolic foci may be evident as areas of infarction, intracapillary thrombosis, or hemorrhage. More commonly, there is a focal necrotizing or diffuse proliferative GN. Immunofluorescent studies show glomerular deposits of IgG, IgM, IgA, and C3 along the GBM and within the mesangium. Electron microscopy reveals typical electron-dense deposits along the GBM and within the mesangium (100, 103, 104).

Early reports suggested that the renal lesions were caused by microemboli from infected vegetations depositing in the kidney, a hypothesis supported by the occasional presence of bacteria within the renal lesions. Most subsequent evidence, however, indicates that immunologic mechanisms rather than emboli are involved in the pathogenesis in most cases: bacteria are rarely found within the kidney, and renal involvement occurs with lesions of the right side of the heart, which would not be likely to embolize to the kidney. Immune complexes containing bacterial antigens are present in the circulation, and both bacterial antigens and bacteria-specific antibodies can be demonstrated within the immune deposits in the kidney. Serum C3 level is usually low, and complement can be found within both the circulating and the deposited immune complexes. These features all support an immune-complex-mediated pathogenesis of the renal injury (100, 103, 104).

Treatment of the endocarditis with antibiotics usually results in resolution of the GN and is associated with the disappearance of immune complexes from the circulation and return of C3 levels to normal. The prognosis of the renal lesions in SBE generally depends on the response of the underlying endocarditis to antibiotics or, in cases of antibiotic failure, to surgical removal of the infective vegetations (105).

Shunt Nephritis

In patients previously treated by shunting for hydrocephalus, there is a well-documented association of GN with infected ventriculoatrial shunts. This condition is another example of an immune-complex nephritis similar to that seen in endocarditis (106). Coagulase-negative staphylococci are the causative organisms in 75% of cases. The clinical and pathologic findings are similar to those in SBE. Presenting features are proteinuria, hematuria, and pyuria, and they may progress to renal failure. Immune complexes containing the bacterial antigens and complement are present in the serum, and C3 is depressed. Histologic findings are those of a diffuse mesangiocapillary GN. Immunofluorescent microscopy demonstrates deposits of immunoglobulin and C3 along the GBM, and bacterial antigen can be demonstrated in the renal lesions (107).

The prognosis for the renal lesion is good if the infection is treated early. This usually involves removal of the infected shunt and administration of appropriate antibiotics (106, 108). The possible progression to end-stage renal disease requires frequent nephrologic monitoring of patients with ventriculoatrial shunts (106). There are a few reports in the literature of a similar renal complication occurring in chronic infection of ventriculoperitoneal shunts.

Other Focal Infections

GN has been reported after chronic abscesses (63), osteomyelitis, otitis media, pneumonia, and other focal infections (Table 52-2 ). Acute renal failure has been the presenting feature of focal infections in various sites, including the lung, pleura, abdominal cavity, sinuses, and pelvis. Many different organisms have been responsible, including S. aureus, Pseudomonas, E. coli, and Proteus species. This is probably another example of immune-complex GN. C3 level is decreased in approximately one-third of reported cases, and immunofluorescent studies reveal diffuse granular deposits of C3 in the glomeruli of all reported instances, with a variable presence of immunoglobulin. The renal lesion is that of MPGN and crescentic nephritis. The renal outcome is reported to be good with successful early treatment of the underlying infection.

Viral Infections

The role of viral infections in the causation of renal disease has been less well defined than that of bacterial infections. Clearly defined associations of renal disease have been made with hepatitis B virus (HBV), hepatitis C virus (HCV), HIV, and hantaviruses, but the role of most other viruses in the pathogenesis of renal disease is not clearly defined. Most viruses causing systemic infection may trigger immunologically mediated renal injury. With increasing application of molecular techniques, it may be that a significant proportion of GNs currently considered to be idiopathic will ultimately be shown to be virus induced. In children with immunodeficiency states and those undergoing renal transplantation, viruses such as cytomegalovirus (CMV) and polyoma virus have been recognized to be associated with nephropathy.

Hepatitis B Virus

Since the discovery of hepatitis B surface antigen (HBsAg) in 1964, hepatitis virus has been shown to infect more than 5% of the world's population and is a major cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma worldwide. Some 350 million people have HBsAg in the circulation (WHO figures). The infection is most common in Africa and the Orient, where it is acquired in childhood by vertical transmission from infected mothers or by horizontal transmission from other children or adults. In developed countries, transmission in adults occurs more often by blood product exposure, sexual contact, or intravenous drug use. The epidemiology of HBV infection in children is changing following the widespread use of effective vaccination at birth, in both developed and developing countries.

HBV is a complex DNA virus with an outer surface envelope (HBsAg) and an inner nucleocapsid core containing the hepatitis B core antigen (HBcAg), DNA polymerase, protein kinase activity, and viral DNA. Incomplete spherical and filamentous viral particles consisting solely of HBsAg are the major viral products in the circulation and may be present in concentrations of up to 1014 particles per mL of serum. Hepatitis B e antigen (HBeAg) can be released from HBcAg by proteolytic treatment and may be found in the circulation either free or complexed to albumin or IgG antibodies. The presence of HBeAg correlates with the presence of complete viral particles and the infectivity of the individual (109).

Infection with HBV may result in either a self-limited infectious hepatitis followed by clearance of the virus and complete recovery, or a chronic or persistent infection in which the immune response is ineffective in eliminating the virus. Chronic HBV infection with continued presence of viral antigens in the circulation caused by an ineffective host immune response provides the best-documented example of immunologically mediated renal injury caused by persistent infection (110). Development of chronic HBV infection is positively associated with infection at a younger age, particularly in infancy, where the rate of chronic infection is up to 90%. In contrast, the likelihood of an acute, symptomatic illness increases with age, to a level where approximately 40% of infections are symptomatic in children above 15 years.

Patterns of Hepatitis B Virus Immunologically Mediated Renal Disease

Prodromal illness

In the early prodromal phase of HBV hepatitis, before the onset of jaundice, some patients develop fever, maculopapular or urticarial rash, and transient arthralgias or arthritis. Occasionally, proteinuria, hematuria, or sterile pyuria are observed. The syndrome usually lasts 3–10 days and often resolves before the onset of jaundice (110, 111). There have been no histologic studies of the renal changes during this prodromal period.

Hepatitis B Virus-Associated Polyarteritis Nodosa

Since 1970, numerous reports have linked HBV infection with polyarteritis nodosa (PAN). Most of these cases have been in adults, but the disorder has also been reported in children (112, 113), where it is estimated that approximately one third of PAN cases are caused by HBV (114). HBV PAN appears to be uncommon in Africa and the Orient, where infection is usually acquired in childhood, and has declined in incidence following the introduction of HBV vaccination (115).

HBV PAN presents weeks to months after a clinically mild hepatitis but may occasionally predate the hepatitis. After a prodromal illness, frank vasculitis affecting virtually any organ appears. Abdominal pain, fever, mononeuritis multiplex, and pulmonary and renal involvement may occur. The renal involvement may appear as hypertension, hematuria, proteinuria, or renal failure (see Chapter 61). Laboratory investigations reveal a florid acute-phase response, leukocytosis, and anemia. Transaminase levels are usually elevated, and HBsAg is present in the circulation. The pathology consists of focal inflammation of small and medium-sized arteries, with fibrinoid necrosis, leukocyte infiltration, and fibrin deposition. Renal pathology may be limited to the medium-sized arteries or may coexist with GN (110, 116).

Circulating immune complexes containing HBsAg and anti-HBs antibodies are usually present in the circulation (110, 116). C3, C4, and total hemolytic complement levels are depressed. HBsAg, IgG, and IgM antibodies to HBV and C3 have been identified by immunofluorescence in the blood vessels (116). A positive ANCA excludes HBV-PAN (115). Although most evidence suggests that the pathogenesis involves an immune-complex-mediated vasculitis, autoantibody or cell-mediated vascular injury may coexist. If the condition is untreated, the mortality is high (112). Most studies suggest that steroids or immunosuppressants help to suppress the vasculitis but potentially predispose to chronic infection or progressive liver disease (110, 112). Successful treatment of hepatitis B-associated PAN with nucleoside analogues such as lamivudine or newer anti-viral drugs, either alone or in combination with interferon-alpha and conventional immunosuppressive therapy, has been reported (117, 118, 119).

Hepatitis B Virus-Associated Membranous Glomerulonephritis

HBV is now the major cause of membranous GN (MGN) in children worldwide. The proportion of patients with MGN caused by HBV is directly related to the incidence of HBsAg in the population, with 80–100% of all cases of MGN in some African and Oriental countries being associated with HBV (110, 120) (see Chapter 26).

HBV MGN usually presents in children aged 2–12. There is a striking male predominance; in the United States, 80% of patients are males (121). The virus is usually acquired by vertical transmission from infected mothers or horizontally from infected family members. Unlike adults with HBV MGN, children do not usually have a history of hepatitis or of active liver disease, but liver function test results are generally mildly abnormal. Liver biopsy specimens may show minimal abnormalities, chronic persistent hepatitis, or (occasionally) more severe changes (121).

The renal manifestations are usually of proteinuria, nephrotic syndrome, microscopic hematuria, or (rarely) macroscopic hematuria. Hypertension occurs in less than 25% of cases, and renal insufficiency is rare.

HBsAg and HBcAg are usually present in the circulation, and HBe antigenemia is seen in a high proportion of cases. Occasionally, HBsAg may be found in the glomeruli but is absent from the circulation. C3 and C4 levels are often low, and circulating immune complexes are found in most cases.

Immunohistologic study reveals deposits of IgG and C3 and (less commonly) IgM and IgA in subepithelial, subendothelial, or mesangial tissue. HBV particles may be seen on electron microscopy, and all the major hepatitis B antigens, including HBsAg, HBcAg, and HBeAg, have been localized in the glomerular capillary wall on immunofluorescence.

Immunologic deposition of HBV and antibody in the glomerular capillary wall is clearly involved in the glomerular injury, but the underlying immunologic events are incompletely understood (110, 122). Passive trapping of circulating immune complexes may be involved, but the circulating immune complexes containing HBsAg are usually larger than would be expected to penetrate the basement membrane. HBsAg and HBcAg are anionic and are therefore unlikely to penetrate the glomerular capillary wall. In contrast, HBeAg forms smaller complexes with anti-HBe antibodies and may readily penetrate the GBM. This may explain the observation that HBeAg in the circulation frequently correlates with the severity of the disease (110). An alternative mechanism for immune-mediated glomerular injury is the trapping of HBV antigens by antibody previously deposited in the kidney. Anti-HBe antibodies are cationic and may readily localize in the glomerulus and subsequently bind circulating antigen and complement. The third possibility is that the depositions of HBV and antibodies are consequences of glomerular injury by cellular mechanisms or autoantibodies. Little evidence supports this view at present (110). A transgenic mouse model of HBV-associated nephropathy has been developed, in which HBsAg and HBcAg is expressed in liver and kidney, particularly tubular epithelial cells, without viral replication. In these mice, gene expression analysis revealed upregulation of acute-phase proteins, particularly C3, although measurable serum C3 levels were reduced. This supports the notion that local persistent expression of HBV viral proteins contributes to HBV-associated nephropathy (123).

Other Hepatitis B Virus Glomerulonephritides

HBV infection has been associated with a variety of other forms of GN in both adults and children. In one small series in children, MPGN was found to be equal in incidence to MGN in the spectrum of HBV-associated GNs (124). Both MPGN and mesangial proliferative GN may be triggered by HBV. In several countries where HBV is common, the proportion of patients with these forms of nephritides who test positive for HBV greatly exceeds the incidence of positivity in the general population (122). As with MGN and HBV-associated PAN, circulating immune complexes and localization of HBV antigens in the glomeruli have been reported in both MPGN and mesangial proliferative GN, and it is likely that similar mechanisms are occurring (110, 125). Several other forms of GN have been associated with HBV, including IgA nephropathy, focal glomerulosclerosis, crescentic nephritis, and systemic lupus erythematosus, but the evidence for these associations is less consistent than for the entities discussed earlier (125).

Treatment of Hepatitis B Virus Glomerulonephritis

HBV is normally cleared as a result of cell-mediated responses in which cytotoxic T cells and natural killer cells eliminate infected hepatocytes. It is not surprising, therefore, that the administration of steroids and immunosuppressive agents either may have no effect on HBV disease or may increase the risk of progressive disease (126). Children with HBV MGN have a good prognosis, and two-thirds undergo spontaneous remission within 3 years of diagnosis. Steroid therapy does not appear to provide any additional benefit (110, 120, 110). Antiviral therapy with pegylated interferon-alpha and lamivudine shows promise in facilitating clearance of HBV, and in some cases, elimination of the infection with antiviral therapy in both children and adults is associated with improvement or resolution of the coexisting renal disease. There is considerable effort being put into the development of newer anti-viral agents which avoid the common problems of resistance associated with lamivudine (127, 128, 129).

Hepatitis C Virus

HCV is an enveloped, single-stranded RNA virus of approximately 9.4 kb in the Flaviviridae family. There are six major HCV genotypes. Hepatitis C is a common disease affecting approximately 400 million people worldwide. In the United States, 4.1 million persons are estimated to be anti-HCV positive, and 3.2 million may be chronically infected (130). An estimated 240,000 children in the United States have antibody to HCV and 68,000–100,000 are chronically infected (131). Children become infected through receipt of contaminated blood products or through vertical transmission. The risk of vertical transmission increases with higher maternal viremia and maternal co-infection with HIV.

Acute HCV infection is rarely recognized in children outside of special circumstances such as a known exposure from an HCV-infected mother or after blood transfusion. Most chronically infected children are asymptomatic and have normal or only mildly abnormal alanine aminotransferase levels. Although the natural history of HCV infection during childhood seems benign in the majority of instances, the infection can take an aggressive course in a proportion of children, leading to cirrhosis and end-stage liver disease during childhood. The factors responsible for this more aggressive course are unidentified (131). Even in adults, the natural history of HCV infection has a variable course, but a significant proportion of patients will develop some degree of liver dysfunction, and 20–30% will eventually have end-stage liver disease as a result of cirrhosis. The risk of hepatocellular carcinoma is significant for those who have established cirrhosis. Hepatitis C is currently the most common condition leading to liver transplantation in adults in the “Western world.”

GN has been described as an important complication of chronic infection with HCV in adults. The clinical presentation is usually of nephrotic syndrome or proteinuria, hypertension, or hematuria, with or without azotemia (132). MPGN, with or without cryoglobulinemia, and MGN are most commonly described. Isolated case reports of other, more unusual patterns of glomerular injury, including IgA nephropathy, focal segmental glomerulosclerosis, crescentic GN, fibrillary GN, and thrombotic microangiopathy, have also been associated with HCV infection (132, 133). Glomerular deposition of hepatitis antigens and antibodies has been described and is believed to play a role in pathogenesis. Cryoglobulinemia is a common accompaniment of GN that is associated with the depression of serum complement levels (132). Renal failure may develop in 40–100% of patients who have MPGN (132, 134). The presence of virus-like particles as well as viral RNA within the kidney sections of patients with HCV-associated glomerulopathies has been reported (135).

The diagnosis should be suspected if glomerular disease is associated with chronic hepatitis, particularly with the presence of cryoglobulins, but renal biopsy is necessary to establish a definitive diagnosis.

HCV infection is relatively common in children with end-stage renal disease and is an important cause of liver disease in this population. Acquisition of HCV infection continues to occur in dialysis patients because of nosocomial spread (136). Elevation of transaminase level is not a sensitive marker of infection in children and HCV enzyme-linked immunosorbent assay or PCR testing should be used to increase sensitivity (137). HCV-infected renal transplant recipients had higher mortality and hospitalization rates than other transplant recipients (138), and HCV infection has been reported to be associated with de novo immune-mediated GN, especially type 1 MPGN, in renal allografts, resulting in accelerated loss of graft function (139, 140).

No large randomized, controlled trials of treatment of children with chronic hepatitis C have been performed, although one study (PEDS-C) is currently recruiting patients into a trial of pegylated interferon +/− ribavirin (141). Small heterogeneous studies of interferon monotherapy have reported sustained virologic response rates of 35–40% (131). In adults, improvement of proteinuria and renal function often follows interferon-alpha treatment (132, 134), but relapses are common after cessation of treatment. Combination of interferon with ribavirin in patients with chronic liver disease has been shown to increase the rate of sustained response in these patients (142). As yet, however, there are few data regarding the use of combination therapy with interferon and ribavirin in children. Moreover, interferon-alpha therapy is associated with acute or subacute renal failure in more than one-third of the patients with renal transplants (143).

Hepatitis C may be complicated by systemic mixed cryoglobulinemic (MC) vasculitis, and in some cases by a polyarteritis nodosa (PAN)-type non-cryoglobulinemic vasculitis (144). Treatment with interferon-α (IFN-α) and ribavirin mostly is associated with an improvement of vasculitic symptoms. In some cases, exacerbation and rarely new onset of vasculitis of the peripheral nervous system have been described after this treatment. In fulminant cases immunosuppressive therapy with steroids, and cyclophosphamide, or rituximab may be needed to control life threatening vasculitis prior to antiviral treatment (144).

Herpes Viruses

Cytomegalovirus

CMV is one of the eight human herpes viruses. Transmission of the virus requires exposure to infected body fluids such as breast milk, saliva, urine, or blood. Individuals initially infected with CMV may be asymptomatic or display nonspecific flu-like symptoms. After the initial infection CMV, like all herpes viruses, establishes latency for life but will be periodically excreted by an asymptomatic host. CMV replicates within renal cells, and on biopsy samples from immunocompromised hosts, viral inclusions can be visualized by light microscopy in cells of the convoluted tubules and collecting ducts (145). Glomerular cells and shed renal tubular cells may have characteristic inclusions, but clinically evident renal disease is rare and is seen virtually only in immunocompromised or congenitally infected children (145, 146).

The clinical manifestations of CMV-induced renal disease in congenitally infected infants are variable and range from asymptomatic proteinuria to nephrotic syndrome and renal impairment. In congenital CMV infection, histologic changes of viral inclusions commonly occur in the tubules. In addition, proliferative GN has been reported, with evidence on electron microscopy of viral immune deposits in glomerular cells (146, 147). In CMV-infected immunocompromised patients, immune-complex GN has been documented with mesangial deposits of IgG, IgA, C3, and CMV antigens within glomeruli. Eluted glomerular immunoglobulins have been shown to contain CMV antigens (148).

CMV is the most common viral infection after kidney transplantation. Experience with pediatric kidney transplant recipients suggests a 67% incidence of CMV infection (149). The direct and indirect effects of CMV infection result in significant morbidity and mortality among kidney transplant recipients. CMV-negative patients who receive a CMV-positive allograft are at risk for primary infection and graft dysfunction. Patients who are CMV seropositive at the time of transplantation are also at risk of reactivation and superinfection. Tubulointerstitial nephritis is a well-characterized pathologic feature of renal allograft CMV disease, which can be difficult to distinguish from injury caused by rejection. Histologic evidence of endothelial cell injury and mononuclear cell infiltration in the glomeruli has been reported (148). CMV glomerular vasculopathy in the absence of tubulointerstitial disease, causing renal allograft dysfunction, has also been reported (150). Beyond the acute allograft nephropathy associated with CMV viremia, CMV is known to cause chronic vascular injury. This may adversely affect the long-term outcome of the allograft and may be the explanation for the observed association with chronic allograft nephropathy (151).

Newer techniques for rapidly diagnosing CMV infection are becoming widely available and include shell vial culture, pp65 antigenemia assay, PCR, and the hybrid-capture RNA-DNA hybridization assay for qualitative detection of CMV PCR. Quantitative plasma PCR testing (PCR viral load) is increasingly used for diagnosis and monitoring of CMV viremia in renal transplant recipients.

Antiviral agents that have been shown to be effective against CMV include ganciclovir, valganciclovir, foscarnet, and cidofovir. Ganciclovir remains the drug of choice for treating established disease. Intravenous ganciclovir therapy is preferred in children because of the erratic absorption of oral ganciclovir. Major limitations of ganciclovir therapy are the induction of renal tubular dysfunction and bone marrow toxicity, principally neutropenia and thrombocytopenia. Dosage adjustments are necessary for recipients with renal dysfunction. Oral valganciclovir is now used for CMV prophylaxis post-transplant (152). Use of other antiviral agents such as foscarnet and cidofovir is limited because of nephrotoxicity and difficulty of administration. A number of reports have demonstrated the effectiveness of high-titer CMV immune globulin therapy in reducing severe CMV-associated disease when used in combination with ganciclovir (149, 153).

Varicella-Zoster Virus

The association of varicella with nephritis has been known for more than 100 years since Henoch reported on four children with nephritis that occurred after the appearance of varicella vesicles. Varicella, however, is rarely associated with renal complications (154). In fatal cases with disseminated varicella and in the immunocompromised individual, renal involvement is more common. Cases in which varicella infection caused GN in renal transplant recipients have been reported (155). Histologic findings in fatal cases include congested hemorrhagic glomeruli, endothelial cell hyperplasia, and tubular necrosis. In mild and nonfatal cases and in non-immunocompromised individuals, varicella is occasionally associated with a variety of renal manifestations, ranging from mild nephritis to nephrotic syndrome and acute renal failure (156). Histologic findings include endocapillary cell proliferation, epithelial and endothelial cell hyperplasia, and inflammatory cell infiltration (154). Rapidly progressive nephritis has also been reported. Immunohistochemical studies reveal glomerular deposition of IgG, IgM, IgA, and C3. On electron microscopy, granular electron-dense deposits have been found in the paramesangial region, and varicella antigens may be deposited in the glomeruli. The features suggest an immune-complex nephritis. Elevated circulating levels of IgG and IgA immune complexes and depressed C3 and C4 levels support this possibility (154).

Fulminant disseminated varicella and varicella in immunocompromised patients should be treated with intravenous acyclovir.

Epstein-Barr Virus

Renal involvement is common during acute infectious mononucleosis, usually manifesting as an abnormal urine sediment, with hematuria in up to 60% of cases. Hematuria, either microscopic or macroscopic, usually appears within the first week of the illness and lasts for a few weeks to a few months. Proteinuria is usually absent or low grade. More severe renal involvement with proteinuria, nephrotic syndrome, or acute nephritis with renal failure is much less common. Acute renal failure may be seen during the course of fulminant infectious mononucleosis with associated hepatic failure, thrombocytopenia, and encephalitis. It is usually caused by interstitial nephritis that is likely the result of immunopathologic injury precipitated by Epstein-Barr virus (EBV) infection. However, the identification of EBV DNA in the kidney raises the possibility that direct infection might play a role (157). The renal involvement must be distinguished from myoglobinuria caused by rhabdomyolysis, which may occur in infectious mononucleosis, and from bleeding into the renal tract as a result of thrombocytopenia.

Renal histologic findings in EBV nephritis are an interstitial nephritis with mononuclear cell infiltration and foci of tubular necrosis. Glomeruli may show varying degrees of mesangial proliferation. On immunohistochemical study, EBV antigens are seen in glomerular and tubular deposits. The prognosis for complete recovery of renal function is good. Treatment with corticosteroids may have a role in the management of EBV-induced acute renal failure and may shorten the duration of renal failure (158).

EBV-associated post-transplantation lymphoproliferative disease is a recognized complication in renal transplant recipients. Latent infection of EBV in renal proximal tubular epithelial cells has recently been described as causing idiopathic chronic tubulointerstitial nephritis (159).

Herpes Simplex Virus

The herpes simplex virus (HSV) causes persistent infection characterized by asymptomatic latent periods interspersed with acute relapses. As with other chronic and persistent infections, immunologically mediated disorders triggered by HSV are well recognized, and it is perhaps surprising that HSV has rarely been linked to nephritis. Acute nephritis and nephrotic syndrome have been associated with herpes simplex encephalitis. Renal histology shows focal segmental GN with mesangial and segmental deposits of IgM, C3, and HSV antigens. As with other herpes viruses, HSV has been suggested as a trigger for IgA nephritis, MPGN, and membranous nephropathy. Elevated levels of HSV antibodies have been reported in patients with a variety of forms of GN, but no conclusive evidence exists of an etiologic role for HSV (160).

Adenovirus and Enterovirus

Adenovirus and enterovirus, are unrelated ubiquitous pathogens that infect large proportions of the population annually and yet are rarely associated with renal disease. The literature contains scattered reports of acute nephritis after infection with each of these viruses.

Adenovirus is a major cause of hemorrhagic cystitis and was implicated as the cause of hemorrhagic cystitis in 23–51% of children with this disorder (161). Boys are affected more often than girls, and hematuria persists for 3–5 days. Microscopic hematuria, dysuria, and frequency may occur for longer periods. Adenovirus types 11 and 21 are the usual strains isolated.

Picornaviruses, including enteroviruses, echovirus and coxsackieviruses, have been linked with acute nephritis and acute renal failure associated with rhabdomyolysis. Coxsackie B virus can be isolated in urine. Direct infection of kidney cells is supported by in vitro work demonstrating lytic infection of human podocyte and proximal tubular epithelial cell cultures, although different strains exhibit variable degrees of nephrotropism. Renal damage in vivo may have both a direct lytic mechanism and an immune-complex basis (162). In the newborn, enteroviruses cause fulminant disease with DIC, shock, and liver failure, and acute renal failure may occur.

Measles Virus

Renal involvement from measles virus is uncommon, although measles virus can be cultured from the kidney in fatal cases. An acute GN has been reported to follow measles with evidence of immune deposits containing measles virus antigen within the glomeruli. The nephritis is generally self-limiting (163).

Mumps Virus

Mild renal involvement is common during the acute phase of mumps infection. One-third of children with mumps have abnormal urinalysis results, with microscopic hematuria or proteinuria. Mumps virus may be isolated from urine during the first 5 days of the illness, at a time when urinalysis findings are abnormal. Plasma creatinine concentrations usually remain normal, despite the abnormal urine sediment, but more severe cases in adults have been associated with evidence of acute nephritis with impaired renal function. Renal biopsy specimens demonstrate an MPGN with deposition of IgA, IgM, C3, and mumps virus antigen in the glomeruli, which suggests an immune-complex-mediated process (164).

Human Immunodeficiency Virus

Despite the increasing availability of interventions to limit vertical HIV transmission, an estimated 1,500 children continue to acquire HIV each day. The World Health Organization estimated that there were 33.2 million people, including 2.1 million children, living with HIV infection at the end of 2007. Of 2.1 million AIDS deaths, 330,000 were in children. The number of children on anti-retroviral treatment (ART) rose from 75,000 in 2005 to almost 200,000 in 2007.

Renal involvement in HIV infection was first described in 1984 in adults (165, 166, 167) and in children (168), and renal involvement occurs in 2–15% of HIV-infected children in the United States (169, 170, 171). Since the development of highly active antiretroviral therapy (HAART), however, the incidence of end-stage renal disease in HIV infection in both adults and children in industrialized countries has declined, but it is predicted that the dramatic decline in AIDS-related deaths will lead to an ageing population of HIV-infected individuals who will be at risk of non-HIV related renal problems, such that the numbers of HIV-positive ESRD patients will increase in the United States (172).

HIV infection is associated with a number of renal pathologies. HIV-associated nephropathy (HIVAN) is a syndrome of glomerular and tubular dysfunction, which can progress to end-stage renal failure. It is discussed more fully below. Glomerular syndromes other than HIVAN include MGN that resembles lupus nephritis and immune-complex GN, with IgA nephropathy and HCV-associated MPGN being the most common forms. There have also been several case reports of amyloid kidney (171, 173, 174). The kidneys may be affected by various other mechanisms. Opportunistic infections with organisms such as BK virus (BKV) that give rise to nephropathy and hemorrhagic cystitis have been reported in association with HIV infection (175). Systemic infections accompanied by hypotension can cause prerenal failure leading to acute tubular necrosis. Acute tubular necrosis has also been reported in HIV patients after the use of nephrotoxic drugs such as pentamidine, foscarnet, cidofovir, amphotericin B, and aminoglycosides. Intratubular obstruction with crystal precipitation can occur with the use of sulfonamides and intravenous acyclovir. Indinavir is well recognized to cause nephropathy and renal calculi (176). MPGN associated with mixed cryoglobulinemia and thrombotic microangiopathy/atypical-cal HUS in association with HIV infections have been reported (177, 178).

HIV-Associated Nephropathy (HIVAN)

HIVAN is characterized by both glomerular and tubular dysfunction, the pathogenesis of which is not entirely known. HIVAN is a clinico-pathologic entity that includes proteinuria, azotemia, focal segmental glomerulosclerosis or mesangial hyperplasia, and tubulointerstitial disease (171). In adults in the United States, there is a markedly increased risk of nephropathy among African American persons with HIV infection. This appears to be true in children as well, but the data are sparse. The spectrum of HIVAN seems to be coincident with the degree of AIDS symptomatology. It is thought that HIVAN can present at any point in HIV infection, but most patients with HIVAN have CD4 counts of less than 200 × 106/200 cells/mL, which suggests that it may be primarily a manifestation of late-stage disease (179).

Although a spectrum of clinicopathologic entities including mesangial hyperplasia, focal segmental glomerulosclerosis, minimal change disease, and systemic lupus erythematosus nephritis has been described, the classic pathologic feature of HIVAN is the collapsing form of focal and segmental glomerulosclerosis (180). In the affected glomeruli, visceral epithelial cells are hypertrophied and hyperplastic, and contain large cytoplasmic vacuoles and numerous protein resorption droplets. There is microcystic distortion of tubule segments, which contributes to increasing kidney size. Podocyte hyperplasia can become so marked that it causes obliteration of much of the urinary space, forming “pseudocrescents” (173). Capillary walls are wrinkled and collapsed with obliteration of the capillary lumina. The interstitium is edematous with a variable degree of T-cell infiltration (181). The Bowman capsule can also be dilated and filled with a precipitate of plasma protein that represents the glomerular ultrafiltrate. One of the most distinctive features of HIVAN, however, is the presence of numerous tubuloreticular inclusions within the cytoplasm of glomerular and peritubular capillary endothelial cells (173). Immunofluorescence testing is positive for IgM and C3 in capillary walls in a coarsely granular to amorphous pattern in a segmental distribution (180, 181).

The presence of the HIV genome in glomerular and tubular epithelium has been demonstrated using complementary DNA probes and in situ hybridization. Proviral DNA has been detected by PCR in the glomeruli, tubules, and interstitium of micro dissected kidneys from patients who had pathologic evidence of HIVAN, but it has also been detected in the kidneys of HIV-positive patients with other glomerulopathies (182). A combination of both proliferation and apoptosis of renal cells may cause the loss of nephron architecture. Apoptosis has been demonstrated in cells in the glomerulus, tubules, and interstitium of biopsy specimens from HIV-positive patients with focal segmental glomerulosclerosis. In addition, the role of various cytokines and growth factors, specifically transforming growth factor beta (TGF-beta), in the development of sclerosis has been studied (183, 184).

Transgenic murine models provide some of the strongest evidence for a direct role of HIV-1 in the induction of HIVAN. These mice do not produce infectious virus but express the HIV envelope and regulatory genes at levels sufficient to re-create the HIVAN that is seen in humans (183). Serial deletion experiments have concluded that the nef and vpr genes are necessary though not sufficient for HIVAN pathogenesis. Additional factors such as genetic predisposition are thought to explain the fact that African Americans have a far greater likelihood of developing HIVAN than other racial groups, and that HIVAN is more likely in patients with a family history of ESRD.

HIVAN can manifest as mild proteinuria, nephrotic syndrome, renal tubular acidosis, hematuria, and/or acute renal failure (168, 169, 170, 171). Nephrotic syndrome and chronic renal insufficiency are late manifestations of HIVAN. Children with HIVAN are likely to develop transient electrolytic disorders, heavy proteinuria, and acute renal failure due to systemic infectious episodes or nephrotoxic drugs.

Early stages of HIVAN can be identified by the presence of proteinuria and “urine microcysts” along with renal sonograms showing enlarged echogenic kidneys. Urinary renal tubular epithelial cells are frequently grouped together to form these microcysts, which were found in the urine of children with HIVAN who had renal tubular injury (171). Advanced stages of HIVAN typically present with nephrotic syndrome with edema, heavy proteinuria, hypoalbuminemia, and few red or white blood cells in urinary sediments. Hypertension may be present, but usually blood pressure is within or below the normal range. HIVAN in adults follows a rapidly progressive course, with end-stage renal disease developing within 1–4 months, but in children this rapid progression does not necessarily occur. Definitive diagnosis of HIVAN should be based on biopsy results, and biopsy should be performed if significant proteinuria is present, because in approximately 50% of HIV-infected patients with azotemia and/or proteinuria (>1 g/24 h) who undergo renal biopsy, the specimen will have histologic features consistent with other renal diseases (179).

When available, HAART should be given to children with symptomatic HIV disease. Specific treatment of HIVAN remains controversial. Several studies have looked at the role of HAART, angiotensin I-converting enzyme (ACE) inhibitors, steroids, and even cyclosporin with somewhat encouraging results. However, as yet no randomized case-controlled trials have been undertaken. Most of the studies have been small and retrospective, and many have included patients both with and without renal biopsy-proven HIVAN. Cyclosporin has been used to treat HIVAN in children with remission of nephrotic syndrome (169). Similar responses have been reported to treatment with corticosteroids in various studies (185, 186, 187, 188). ACE inhibitors have been used with encouraging results (189).

The general regimen used to treat patients with HIV, including HAART, should be applied to children with HIVAN. The dosages of some medications must be adjusted to the patients glomerular filtration. There are reports of spontaneous regression of HIVAN with supportive management and treatment with HAART, particularly with regimes containing protease inhibitors (190, 191, 192, 193). It should be emphasized that the improvement reported with other modalities of treatment such as corticosteroids, cyclosporin, and ACE inhibitors always occurs when these agents are given in conjunction with antiretroviral therapy.

The kidneys of transgenic mice have been found to have elevated levels of TGF-beta messenger RNA and protein (184). Furthermore, gene expression analysis on tubular epithelial cells from a patient with HIVAN found upregulation of several inflammatory mediator genes downstream of interleukin 6 and of the transcription factor NFkB (194). Several other therapeutic options have been suggested, aimed specifically at the presumed role of TGF-beta in the pathogenesis of HIVAN. Treatment directed at its synthesis using gene therapy to block TGF-beta gene expression is being explored. Therapy directed at decreasing the activity of TGF-beta using anti-TGF-beta antibodies or other inhibitory substances is also an area of investigation. In addition, blocking renal receptors for chemokines such as RANTES (regulated upon derivation, normal T cell expressed and secreted), interleukin-8, and monocyte-chemoattractant protein-1 has been proposed as another possible treatment alternative (195).

In the HAART era, the outlook for HIV patients with ESRD has improved, but these patients fare worse than ESRD patients without HIV (196). Most reports of HIV-infected patients on hemodialysis have shown poor prognosis, with mean patient survival times ranging from 14–47 months. Mortality is therefore still close to 50% within the first year of dialysis. In general, improved survival is associated with younger age at initiation of hemodialysis and with higher CD4 counts. Access complications such as infection and thrombosis tend to occur at a higher rate in HIV-infected hemodialysis patients. Cross infection with HIV in dialysis patients is very rare. No patient-to-patient HIV transmission has yet been reported in a hemodialysis unit in the United States, although several such cases have occurred in South America (195, 197).

Peritoneal dialysis is an alternative for HIV-infected patients. The incidence of peritonitis varies across studies, but some studies did report a higher incidence of Pseudomonas and fungal peritonitis in the HIV-positive population (195). Infections with unusual organisms such as Pasteurella multocida, Trichosporon beigelii, and Mycobacterium avium intracellulare complex have also been reported. Several studies, however, have suggested that there is no significant difference between the HIV-infected and non-HIV-infected populations. Of note is that virus capable of replication in vitro has been recovered from the peritoneal dialysis effluent, and it can be recoverable for up to 7 days in dialysis bags at room temperature and for up to 48 h in dry exchange tubing (195).

Previously, long-term dialysis had been thought to be preferable to renal transplantation, primarily because of the concern that the immunosuppressive therapy required after transplantation could promote progression of HIV/AIDS. A multicenter prospective study has been addressing these questions (198). Data so far indicate that the outcome for liver and kidney transplantation is not considerably different from patients without HIV, with good graft persistence, and a low rate of development of opportunistic infections in those with well-controlled HIV and relatively high CD4 counts (199).

Human Polyoma Viruses

The human polyoma viruses are members of the papovavirus family and have received increasing attention as pathogens in immunocompromised patients. They are nonenveloped viruses ranging in size from 45–55 nm, with a circular, double-stranded DNA genome that replicates in the host nucleus. The best-known species in this genus are the BKV, the JC virus (JCV), and the simian virus SV40. BKV was first isolated from the urine of a 39-year-old man who developed ureteral stenosis 4 months after renal transplantation (200). The name of the virus refers to the first patients initials, which is also true of JCV. BKV establishes infection in the kidney and the urinary tract, and its activation causes a number of disorders, including nephropathy and hemorrhagic cystitis. BKV-associated nephropathy has become an increasingly recognized cause of renal dysfunction in renal transplantation patients (201, 202, 203, 204, 205). JCV establishes latency mainly in the kidney, and its reactivation can result in the development of progressive multifocal leukoencephalopathy. There are a few reports of nephropathy in association with JCV infection (see references in (206)), but BKV poses a much bigger problem in this regard. Recent studies have reported SV40 in the allografts of children who received renal transplants and in the urine, blood, and kidneys of adults with focal segmental glomerulosclerosis, which is a cause of end-stage renal disease and an indication for kidney transplantation (207).

BKV infection is endemic worldwide

Seroprevalence rates as high as 60–80% have been reported among adults in the United States and Europe. The peak incidence of primary infection (as measured by acquisition of antibody) occurs in children 2–5 years of age. BKV antibody may be detected in as many as 50% of children by 3 years of age, and in 60–100% of children by 9 or 10 years of age; antibodies wane thereafter. BKV infection may be particularly important in the pediatric transplantation population, in whom primary infection has a high probability of occurring while the children are immunosuppressed (208).

Primary infection with BKV in healthy children is rarely associated with clinical manifestations. Mild pyrexia, malaise, vomiting, respiratory illness, pericarditis, and transient hepatic dysfunction have been reported with primary infection. Investigators hypothesize that after an initial round of viral replication at the site of entry, viremia follows with dissemination of the virus to distant sites at which latent infection is established. The most frequently recognized secondary sites of latent infection are renal and uroepithelial cells. Secondary infection has been reported to cause tubulointerstitial nephritis and ureteral stenosis in renal transplantation patients. It may be that renal impairment in immunocompromised patients and in non renal solid organ transplant recipients is found to be frequently associated with BKV infection.

BK Virus Nephropathy in Patients Undergoing Renal Transplantation

The reported prevalence of BKV nephropathy in renal allografts is between 1 and 8% (201, 202, 205, 209, 210). Asymptomatic infection is characterized by viral shedding without any apparent clinical features. Viruria, resulting from either primary or secondary infection, can persist from several weeks to years. Tubulointerstitial nephritis associated with BKV in renal transplant recipients is accompanied by histopathologic changes, with or without functional impairment. “Infection” and “disease” must be differentiated carefully. BKV infection (either primary or reactivated) can progress to BKV disease, but will not always do so (208). Furthermore, not all cases of BKV disease lead to renal impairment. However, infection can progress to transplant dysfunction and graft loss, although the diagnosis may be complicated by the coexistence of active allograft rejection.

BKV nephritis is reported to have a bimodal distribution, with 50% of BKV-related interstitial nephritis cases occurring 4–8 weeks after transplantation and the remainder of patients developing disease months to years after transplantation (211). Allograft failure is due mainly to extensive viral replication in tubular epithelial cells leading to frank tubular necrosis (203). Although damage is potentially fully reversible early in the disease, persisting viral damage leads to irreversible interstitial fibrosis. Tubular atrophy and allograft loss has been observed in 45% of affected patients (203, 212).

In most cases, BKV nephropathy in adult renal transplant recipients represents a secondary infection associated with rejection and its treatment. In children, however, primary BKV infection giving rise to allograft dysfunction may occur (208).

The definitive diagnosis of BKV nephropathy requires renal biopsy. Histopathologic features include severe tubular injury with cellular enlargement, marked nuclear atypia, epithelial necrosis, denudation of tubular basement membranes, focal intratubular neutrophilic infiltration, and mononuclear interstitial infiltration, with or without concurrent tubulins. This constellation of histologic features, particularly severe tubulitis, is often misinterpreted as rejection, even by the experienced pathologist. The presence of well-demarcated basophilic or amphophilic intranuclear viral inclusions, primarily within the tubular and parietal epithelium of the Bowman capsule, can help distinguish BKV disease from rejection (202, 203, 205). Additional tests such as immunohistochemistry, PCR analysis, or electron microscopy of biopsied tissue aimed at the identification of BKV may be required.

A practical diagnostic approach for identifying BKV in renal transplant patients is summarized in Table 52-3 .
Table 52-3

Diagnosis of bk virus (bkv) in renal transplant recipients

Tests

Comments

 

Urine

 

Cytology: decoy cells BKV PCR

Presence of BKV by PCR or decoy cells in urine signifies BKV replication. Decoy cells are caused by infection of the urinary epithelial cells with HPV. The nuclei are enlarged and nuclear chromatin is completely homogenized by viral cytopathic effect. Positive PCR results for BKV viruria and presence of decoy cells have poor predictive value. Specificity is increased if >10 cells/Cytospin along with presence of inflammatory cells.

 

Serum

 

Antibody assays BKV BKV PCR

Presence of antibody is usually indicative of previous infection; however, positive results for BKV DNA PCR on serum signifies BK viremia. BKV PCR testing of plasma has proven to be a sensitive (100%) and specific (88%) means to identify BKV-associated nephropathy in adults. Viral load has also been used to monitor infection and clearance. However, because primary infection occurs in childhood, it might not be applicable to the pediatric population.

 

Tissue

 

Histopathology, electron microscopy, BKV PCR

The definitive diagnosis of BKV nephropathy requires renal biopsy. Histopathology might mimic rejection or drug toxicity. However, characteristic findings have been described. Electron microscopy and immune staining are helpful in confirming the diagnosis. PCR assays of viral load in tubular cells have been reported to be a sensitive marker for diagnosis and monitoring.

 

HPV, human polyoma virus; PCR, polymerase chain reaction

Other Implications of BK Virus in Renal Transplantation

BKV infection may cause ureteral obstruction due to ureteral ulceration and stenosis at the ureteric anastomosis. BKV-associated ureteral stenosis has been reported in 3% of renal transplant patients and usually occurs between 50 and 300 days after transplantation. Ulceration due to inflammation, proliferation of the transitional epithelial cells, and smooth muscle proliferation may lead to partial or total obstruction.

High-level BKV replication is implicated in acute, late-onset, long-duration hemorrhagic cystitis after bone marrow transplantation (213).

There are two case reports in children of renal carcinomas arising in the transplanted kidney in association with BK virus nephropathy. It remains unclear whether BK virus itself has oncogenic potential in the transplant setting, but this is possible given that the big T antigen (T-Ag) expressed by polyomavirus family viruses has been shown to have the ability to disrupt chromosomal integrity (214, 215).

Treatment

Whether patients with asymptomatic viremia or viruria need specific therapeutic intervention is not certain. Review of the literature suggests that careful reduction of immune suppression, combined with active surveillance for rejection, will result in clinical improvement. Reduction in immunosuppression may precipitate episodes of acute cellular rejection, which need to be judiciously treated with corticosteroids. The outcome of BKV nephropathy is unpredictable, and stabilization of renal function may occur regardless of whether maintenance immunotherapy is altered or not (216).

Some reports favor the use of cidofovir. Cidofovir has important nephrotoxic side effects in the usual therapeutic dosage recommended for the treatment of CMV infection, and for BKV nephropathy a reduced dosage regime is generally used. The efficacy of cidofovir in reducing viremia has been demonstrated (see review in (210)). However, spontaneous clearance of viral infection after reduction of immunosuppression (without cidofovir) has also been reported. There are also case studies of the use of leflunamide.

Presence of BKV by PCR or decoy cells in urine signifies BKV replication. Decoy cells are caused by infection of the urinary epithelial cells with human polyoma viruses. The nuclei are enlarged and nuclear chromatin is completely homogenized by viral cytopathic effect. Positive PCR results for BKV viruria and presence of decoy cells have poor predictive value. Specificity is increased if >10 cells/Cytospin along with presence of inflammatory cells.

Presence of antibody is usually indicative of previous infection; however, positive results for BKV DNA PCR on serum signifies BK viremia. BKV PCR testing of plasma has proven to be a sensitive (100%) and specific (88%) means to identify BKV-associated nephropathy in adults. Viral load has also been used to monitor infection and clearance. However, because primary infection occurs in childhood, it might not be applicable to the pediatric population.

The definitive diagnosis of BKV nephropathy requires renal biopsy. Histopathology might mimic rejection or drug toxicity. However, characteristic findings have been described. Electron microscopy and immune staining are helpful in confirming the diagnosis. PCR assays of viral load in tubular cells have been reported to be a sensitive marker for diagnosis and monitoring.

Viral Hemorrhagic Fever

Viral hemorrhagic fever involves at least 12 distinct RNA viruses that share the propensity to cause severe disease with prominent hemorrhagic manifestations (Table 52-4 ). The viral hemorrhagic fevers, widely distributed throughout both temperate and tropical regions of the world, are important causes of mortality and morbidity in many countries. Most viral hemorrhagic fevers are zoonoses (with the possible exception of dengue virus), in which the virus is endemic in animals and human infection is acquired through the bite of an insect vector. Aerosol and nosocomial transmissions from infected patients are important for Lassa, Junin, Machupo, and Congo-Crimean hemorrhagic fevers, and Marburg and Ebola viruses (217).
Table 52-4

Viral hemorrhagic fevers (hf)

Virus

Geographic distribution

Source of human infection

Incubation period (days)

Renal involvement

Renal pathology

Treatment

 

Dengue

Tropical Africa, South America, Asia

Mosquito

5–8

Rare, only in Dengue HF or shock

Vasomotor nephropathy, immune complex

Supportive

 

Yellow fever

Africa, South America

Mosquito

3–6

Common

Vasomotor nephropathy

Supportive

 

Congo-Crimean

Eastern Europe, Africa, Asia

Tick, nosocomial

2–7

In severe cases

Vasomotor nephropathy

Supportive ? Ribavirin

 

Hantaan viruses (Puumala, Seoul strains)

Europe, Asia, Africa, America

Rodents

4–42

HF and renal syndrome (Korean, Chinese, and Japanese epidemic HF, nephropathia epidemica)

Vasomotor nephropathy Interstitial nephropathy

Supportive ? Ribavirin

 

Rift Valley fever

Sub-Saharan Africa

Mosquito, contact with infected animals

3–7

Rare, only in fulminant cases

Vasomotor nephropathy

Supportive

 

Lassa fever

West Africa

Rodents, nosocomial

3–16

In cases with shock

Vasomotor nephropathy

Supportive and ribavirin

 

Junin, Argentine HF

Argentina

Rodents, nosocomial

5–19

In cases with shock

Vasomotor nephropathy

Supportive

 

Machupo, Bolivian HF

Bolivia

Rodents, nosocomial

5–19

In cases with shock

Vasomotor nephropathy

Supportive

 

Marburg

Africa

?, nosocomial

5–10

In cases with shock

Vasomotor nephropathy

Supportive

 

Ebola

Africa

?, nosocomial

5–10

In cases with shock

Vasomotor nephropathy

Supportive

 

Omsk

Eastern Europe

Tick

2–4

In cases with shock

Vasomotor nephropathy

Supportive

 

Kyasanur forest

India

Tick

3–8

In cases with shock

Vasomotor nephropathy

Supportive

 

Viral hemorrhagic fevers have many clinical similarities but also important differences in their severity, major organs affected, prognosis, and response to treatment. In all viral hemorrhagic fevers, severe cases occur in only a minority of those affected; subclinical infection or nonspecific febrile illness occurs in the majority. Fever, myalgia, headache, conjunctival suffusion, and erythematous rash occur in all the viral hemorrhagic fevers (218). Hemorrhagic manifestations range from petechiae and bleeding from venepuncture sites to severe hemorrhage into the GI tract, kidney, and other organs. A capillary leak syndrome, with evidence of hemoconcentration, pulmonary edema, oliguria, and ultimately shock, occurs in the most severely affected patients (218). Renal involvement occurs in all the viral hemorrhagic fevers, proteinuria is common, and prerenal failure is seen in all severe cases complicated by shock. However, in Congo-Crimean hemorrhagic fever and hemorrhagic fever with renal syndrome (HFRS), an interstitial nephritis, which may be hemorrhagic, is characteristic, and renal impairment is a major component of the illness.

Dengue

Dengue is caused by a flavivirus that is endemic and epidemic in tropical America, Africa, and Asia, where the mosquito vector Aedes aegypti is present (219). Classic dengue is a self-limited nonfatal disease; dengue hemorrhagic fever and dengue shock syndrome, which occur in a minority of patients, have a high mortality if not aggressively treated with fluids. After an incubation period of 5–8 days, the illness begins with fever, headache, arthralgia, weakness, vomiting, and hyperesthesia. In uncomplicated dengue the fever usually lasts 5–7 days. Shortly after onset a maculopapular rash appears, sparing the palms and the soles, and is occasionally followed by desquamation. Fever may reappear at the onset of the rash.

In dengue hemorrhagic fever and dengue shock syndrome, the typical febrile illness is complicated by hemorrhagic manifestations, ranging from a positive tourniquet test result or petechiae to purpura, epistaxis, and GI bleeding with thrombocytopenia and evidence of a consumptive coagulopathy. Increased capillary permeability is suggested by hemoconcentration, edema, and pleural effusions (219). In severe cases, hypotension and shock supervene, largely as a result of hypovolemia. Renal manifestations include oliguria, proteinuria, hematuria, and rising urea and creatinine. Acute renal failure occurs in patients with severe shock, primarily as a result of renal underperfusion. However, glomerular inflammatory changes may also occur. Children with dengue hemorrhagic fever show hypertrophy of endothelial and mesangial cells, mononuclear cell infiltrate, thinning of basement membranes, and deposition of IgG, IgM, and C3. Electron microscopy shows viral particles within glomerular mononuclear cells (220).

The diagnosis of dengue is made by isolation of the virus from blood or by serologic testing. There is no specific antiviral treatment, and management of patients with dengue shock syndrome or dengue hemorrhagic fever depends on aggressive circulatory support and volume replacement with colloid and crystalloid (221, 222). With correction of hypovolemia, renal impairment is usually reversible, but dialysis may be required in patients with established acute renal failure.

Yellow Fever

Yellow fever is caused by a flavivirus, and is transmitted by mosquito bites, typically Aedes species. It remains an important public health problem in Africa and South America. Renal manifestations are common and include albuminuria and oliguria. Over the next few days after first manifestation of infection, shock, delirium, coma, and renal failure develop, and death occurs 7–10 days after onset of symptoms. Laboratory findings include thrombocytopenia and evidence of hemoconcentration, rising urea and creatinine levels, hyponatremia, and deranged liver function test results. Pathologic findings include necrosis of liver lobules, cloudy swelling and fatty degeneration of the proximal renal tubules, and, often, petechiae in other organs. The oliguria appears to be prerenal and is due to hypovolemia; later, acute tubular necrosis supervenes. At present, there is no effective antiviral agent for yellow fever.

Congo-Crimean Hemorrhagic Fever

Congo-Crimean hemorrhagic fever, first recognized in the Soviet Union, is now an important human disease in Eastern Europe, Asia, and Africa (223). Severely affected patients become stuporous or comatose 5–7 days into the illness, with evidence of hepatic and renal failure and shock. Proteinuria and hematuria are often present. The disease is fatal in 15–50% of cases. The virus is sensitive to ribavirin, but in one small trial of i.v. ribavirin versus supportive treatment only, there was no significant improvement in outcome in the treatment group (224).

Rift Valley Fever

Rift Valley fever is found in many areas of sub-Saharan Africa. In humans, most infections follow mosquito bites or animal exposure. The infection may present as an uncomplicated febrile illness, with muscle aches and headaches. In 10% of patients, encephalitis or retinal vasculitis occurs as a complication. In a small proportion of cases, a fulminant and often fatal hemorrhagic illness occurs with hematemesis, melena, epistaxis, and evidence of profound DIC. Severe hepatic derangement, renal failure, and encephalopathy are often present. Despite intensive care, mortality is high.

Hemorrhagic Fever and Renal Syndrome (Hantavirus)

The viruses causing HFRS all belong to the Hantavirus genus in the Bunyaviridae family. The hantaviruses are distributed worldwide and are maintained in nature through chronic infection of rodents and small mammals. Transmission to humans is by aerosolized infectious excreta. Human disease usually occurs in summer among rural populations with exposure to rodent-infested barns or grain stores. Urban transmission can occur, however. At least five hantaviruses are known to cause HFRS: Hantaan, Seoul, Puumala, Porogia, and Belgrade viruses (225). HFRS is endemic in a belt from Norway in the west through Sweden, Finland, the Soviet Union, China, and Korea to Japan in the east. The clinical severity of HFRS varies throughout this belt (226). Clinical entities include Korean hemorrhagic fever, nephropathia epidemica in Scandinavia, and epidemic hemorrhagic fever in Japan and China.

In general, HFRS due to Hantaan, Porogia, and Belgrade viruses is more severe and has higher mortality than that due to Puumala virus (nephropathia epidemica) or Seoul virus. Hantaan is predominant in the Far East, Porogia and Belgrade in the Balkans, and Puumala in Western Europe; Seoul has a worldwide distribution (225). The clinical features of the disease vary. The incubation period is 4–42 days. Although HFRS occurs with the same clinical picture in children as in adults, both incidence rates and antibody prevalence rates are very low in children under 10 years of age. Men of working age make up the bulk of clinical cases (226). Mild cases are indistinguishable from other febrile illnesses. In more severe cases, fever, headache, myalgia, abdominal pain, and dizziness are associated with the development of periorbital edema, proteinuria, and hematuria. There is often conjunctival injection, pharyngeal injection, petechiae, and epistaxis or GI bleeding. The most severely affected patients develop shock and renal failure. The disease usually passes through five phases: febrile, hypotensive, oliguric, diuretic, and convalescent. Laboratory findings include anemia, lymphocytosis, thrombocytopenia, prolonged prothrombin and bleeding times, and elevated levels of fibrin degradation products. Liver enzyme levels are elevated, and urea and creatinine levels are elevated during the oliguric phase. Proteinuria and hematuria are consistent findings.

The renal histopathologic findings are those of an interstitial nephritis with prominent hemorrhages in the renal medullary interstitium and renal cortex. Acute tubular necrosis may also be seen. Immunohistochemical analysis reveals deposition of IgG and C3, and the GBM, mesangial, and subendothelial deposits may be seen on electron microscopy (227).

Recovery from Hantavirus-associated disease is generally complete, although chronic renal insufficiency is a rare sequela of HFRS. In mildly affected patients, the disease is self-limiting and spontaneous recovery occurs. However, in severe cases, with shock, bleeding, and renal failure, dialysis and intensive circulatory support may be required (228). Mortality rates vary depending on the strain of virus; rates are 5–15% for hemorrhagic fever and renal syndrome in China and significantly lower for the milder Finnish form associated with the Puumala virus strain.

Ribavirin is active against Hantaan viruses in vitro, and clinical trials indicate that both mortality and morbidity can be reduced by treatment with this antiviral agent if it is administered early in the course of illness. Dosages of 33 mg/kg followed by 16 mg/kg every 6 h for 4 days and then 8 mg/kg every 8 h for 3 days have been used (229).

Lassa Fever

Lassa fever is a common infection in West Africa, caused by an arenavirus, and usually manifests as a nonspecific febrile illness. In 10% of cases, a fulminant hemorrhagic disease occurs. In severe cases, proteinuria and hematuria are usually present, and renal failure may occur. Ribavirin is effective in decreasing mortality. As in other hemorrhagic fevers, intensive hemodynamic support and correction of the hemostatic derangements are important components of therapy (230).

Argentine and Bolivian Hemorrhagic Fevers

Junin and Machupo viruses, the agents of Argentine and Bolivian hemorrhagic fever, respectively, cause hemorrhagic fevers with prominent neurologic features and systemic and hemorrhagic features similar to those of Lassa fever. Oliguria, shock, and renal failure occur in the most severe cases.

Marburg Disease and Ebola Hemorrhagic Fever

Marburg and Ebola viruses have been associated with outbreaks of nosocomially transmitted hemorrhagic fever. Both viruses cause fulminant hemorrhagic fever. Onset is with high fever, headache, sore throat, myalgia, and profound prostration. An erythematous rash on the trunk is followed by hemorrhagic conjunctivitis, bleeding, impaired renal function, shock, and respiratory failure. The mortality rate is high. Renal histopathologic findings in fatal cases are of tubular necrosis, with fibrin deposition in the glomeruli. There is no specific treatment for these disorders.

Emerging Viral Infections

The important role played by a number of other recently characterized viruses is only now being recognized, as improved molecular diagnostic techniques allow identification of hitherto unrecognized viruses. Two examples of recently described viruses are metapneumovirus (237) and bocavirus (238). While both have significant prevalence, and may make an important contribution to the burden of childhood viral infection, as yet there are no reports indicative of significant renal pathology in association with these infections.

Influenza H5N1

Influenza virus has been linked with nephritis and acute renal failure. An emerging infectious disease is avian flu, caused by highly pathogenic H5N1 strains which have hitherto been confined to an avian reservoir, and there have been several outbreaks of infection in humans, particularly in the first part of this decade. Commonly, these patients develop a flu-like illness with prominent respiratory and gastrointestinal symptoms. Renal failure may develop alongside multi-organ failure in the context of acute respiratory distress syndrome (231). As yet, there is no clear correlation of degree of initial renal insufficiency, and outcome (232). There is little data available on treatment, but based on the known resistance patterns of H5N1 strains, oseltamivir and zanamivir are the preferred agents to be used for treatment of infection with H5N1.

SARS

Severe Acute Respiratory Syndrome (SARS) is a newly-emerged infectious disease which was first seen in South China in 2002. It is caused by a SARS coronavirus (SARS CoV). Predominantly, it causes a viral pneumonia, with diffuse alveolar damage; it has considerable mortality (233). Renal effects are not generally significant in the pathophysiology of SARS. However, SARS CoV has been found in kidney tissue at post-mortem (234) (235). SARS CoV enters cells via Angiotensin Converting Enzyme 2 (ACE2) (236), and it is thought that the invasion of kidney tissue reflects the virus’ tropism for ACE2, which is expressed on kidney cells.

Parasitic Infections

Chronic exposure to infectious agents is a major factor in the increased prevalence of glomerular diseases in developing countries. Malaria is the best-documented parasitic infection associated with glomerular disease, but other parasitic infections including schistosomiasis, filariasis, leishmaniasis, and possibly helminth infections may also induce nephritis or nephrosis.

Malaria and Renal Disease

Malaria is estimated to cause up to 500 million clinical cases of illness and more than 1 million deaths each year (239). The association of quartan malaria and nephritis has been well known in both temperate and tropical zones since the end of the nineteenth century.

Epidemiologic studies provide the most conclusive evidence for a role of Plasmodium malariae in glomerular disease (240, 241). Chronic renal disease was a major cause of morbidity and mortality in British Guiana in the 1920s. The frequent occurrence of P. malariae in the blood of these patients led to detailed epidemiologic studies that implicated malaria as a cause of the nephrosis. After the eradication of malaria from British Guiana, chronic renal disease ceased to be a major cause of death in that country (240).

The link between malaria and nephrotic syndrome was strengthened by studies in West Africa in the 1950s and 1960s that demonstrated a high prevalence of nephrotic syndrome in the Nigerian population (242). The pattern of nephrotic syndrome differed from that in temperate climates, with an older peak age, extremely poor prognosis, and unusual histologic features. The incidence of P. malariae parasitemia in patients with the nephrotic syndrome in Nigeria was vastly in excess of that occurring in the general population, whereas the incidence of Plasmodium falciparum parasitemia was similar to that in the general population. The age distribution of nephrotic syndrome also closely paralleled that of P. malariae infection (242). In some affected patients, circulating immune complexes and immunoglobulin, complement, and antigens were present in the glomeruli that were recognized by P. malariae-species antisera.

There is now a view that the patterns of childhood renal disease described in the last century may no longer be representative of the current situation. The variable patterns of renal disease throughout Africa may no longer reflect a dominant role for “malarial glomerulopathy,” and the relative causative role of tropical infections in nephropathy remains an unanswered question (243).

Clinical and Histopathologic Features of Quartan Malaria Nephropathy

Most patients have poorly selective proteinuria and are unresponsive to treatment with steroids or immunosuppressive agents. The characteristic lesions of P. malariae nephropathy are capillary wall thickening and segmental glomerular sclerosis, which lead to progressive glomerular changes and secondary tubular atrophy (242). Cellular proliferation is conspicuously absent. Electron microscopy shows foot-process fusion, thickening of the basement membrane, and increase in subendothelial basement membrane-like material. Immunofluorescent studies show granular deposits of immunoglobulin, complement, and P. malariae antigen in approximately one-third of patients.

In addition to the histologic pattern, termed quartan malaria nephropathy, P. malariae infection is associated with a variety of other forms of histologic appearance, including proliferative GN and MGN (244).

Although quartan malaria nephropathy has been clearly linked to P. malariae infection in Nigeria, a number of studies from other regions in Africa have not revealed the typical histopathologic findings described in the Nigerian studies (245). Furthermore, quartan malaria nephropathy may be seen in children with no evidence of P. malariae infection or deposition of malaria antigens in the kidney. This, together with the fact that antimalarial treatment does not affect the progression of the disorder, raises the possibility that factors other than malaria might be involved in the initiation and perpetuation of the disorder. Although there is undoubtedly a strong association between P. malariae infection and nephrotic syndrome on epidemiologic grounds, the direct causal link is not proven. Most likely, a number of different infectious processes, including malaria, hepatitis B, schistosomiasis, and perhaps other parasitic infections that cause chronic or persistent infections and often occur concurrently in malaria areas, may all result in glomerular injury and a range of overlapping histopathologic features. The prognosis for the nephrotic syndrome in most African studies has been poor, regardless of whether the histologic findings were typical of quartan malaria nephropathy or whether P. malariae parasitemia was implicated. Treatment with steroids and azathioprine is generally ineffective, and a significant proportion of patients progress to renal failure.

Disease Associated with Plasmodium Falciparum Infection

P. falciparum appears to be much less likely to cause significant glomerular pathology. Epidemiologic studies have failed to show a clear association between P. falciparum parasitemia and the nephrotic syndrome. Whereas renal failure appears to be a common complication of severe malaria in adults, it seldom occurs in children.

Renal biopsy specimens from adult patients with acute P. falciparum infections who have proteinuria or hematuria show evidence of glomerular changes, including hypercellularity, thickening of basement membranes, and hyperplasia and hypertrophy of endothelial cells (246). Electron microscopy reveals electron-dense deposits in the subendothelial and paramesangial areas. Deposits of IgM, with or without IgG, are localized mainly in the mesangial areas. P. falciparum antigens can be demonstrated in the mesangial areas and along the capillary wall, which suggests an immune-complex GN. The changes, generally mild and transient, are probably unrelated to the acute renal failure that may complicate severe P. falciparum infection (246). Heavily parasitized erythrocytes play a central role in the various pathologic factors (247).

Renal failure occurring in severe P. falciparum malaria is usually associated with acidosis, volume depletion, acute intravascular hemolysis or heavy parasitic infection that leads to acute tubular necrosis. Recent studies have confirmed an important role for volume depletion in children with severe falciparum malaria, who characteristically have evidence of tachycardia, tachypnoea, poor perfusion and in severe cases hypotension (248). Volume expansion with either colloid or crystalloid results in improvement in hemodynamic indices and reduction in acidosis (249). There is growing evidence that volume expansion with albumin is associated with a better outcome than saline or synthetic colloids (250, 251). Treatment with antimalarials, correction of hypoglycemia and electrolyte imbalance, and volume expansion reduces mortality to less than 5%. Although renal failure is usually associated with infection by P. falciparum, acute renal failure has been described with Plasmodium vivax infection and mixed infections (252).

Blackwater Fever

The term blackwater fever refers to the combination of severe hemolysis, hemoglobinuria, and renal failure. It was more common at the start of the twentieth century in nonimmune individuals receiving intermittent quinine therapy for P. falciparum malaria. Blackwater fever has become rare since 1950, when quinine was replaced by chloroquine. However, the disease reappeared in the 1990s, after the reuse of quinine because of the development of chloroquine-resistant organisms. Since then, several cases have been described after therapy with halofantrine and mefloquine, two new molecules similar to quinine (amino-alcohol family) (253). Renal failure generally occurred in the context of severe hemolytic anemia, hemoglobinuria, and jaundice. The pathophysiology of the disorder is unclear; however, it appears that a double sensitization of the red blood cells to the P. falciparum and to the amino-alcohols is necessary to provoke the hemolysis. Histopathologic findings include swelling and vacuolization of proximal tubules, necrosis and degeneration of more distal tubules, and hemoglobin deposition in the renal tubules. Recent studies indicates a better outcome with earlier initiation of intensive care and dialysis combined with necessary changes in antimalarial medications.

Schistosomiasis

Schistosomiasis affects 200 million people living in endemic areas of Asia, Africa, and South America (254). The infection is usually acquired in childhood, but repeated infections occur throughout life. Schistosoma japonicum is found only in the Orient, whereas Schistosoma haematobium occurs throughout Africa, the Middle East, and areas of southwest Asia. Schistosoma mansoni is widespread in Africa, South America, and southwest Asia.

Human infection begins when the cercarial forms invade through the skin, develop into schistosomula, and move to the lungs via the lymphatics or blood. They then migrate to the liver and mature in the intrahepatic portal venules, where male:female pairing takes place. The adult worm pairs then migrate to their final resting site - the venules of the mesenteric venous system of the large intestine (S. mansoni) or in the venules of the urinary tract (S. haematobium). The females release large numbers of eggs, which may remain embedded in the tissues, embolize to the liver or lungs, or pass into the feces or urine.

Clinical manifestations may occur at any stage of the infection. Cercarial invasion may cause an intense itchy papular rash. Katayama fever is an acute serum sickness-like illness that occurs several weeks after infection, as eggs are being deposited in the tissues. Deposition of the eggs in tissues results in inflammation of the intestines, fibrosis of the liver, and portal hypertension. With S. haematobium, chronic inflammation and fibrosis of the ureters and bladder may lead to obstructive uropathy (255).

Renal manifestations of schistosomiasis occur most commonly in S. mansoni infection. Schistosomal nephropathy usually presents with symptoms including granulomatous inflammation in the ureters and bladder, but glomerular disease (probably on an immune-complex basis) may also occur. Renal disease usually occurs in older children or young adults with long-term infection, but serious disease may also occur in young children (255).

The early renal tract manifestations of schistosomiasis are suprapubic discomfort, frequency, dysuria, and terminal hematuria. In more severe cases, evidence of urinary obstruction appears. Poor urinary stream, straining on micturition, a feeling of incomplete bladder emptying, and a constant urge to urinate may be severely disabling symptoms. The fibrosis and inflammation of ureters, urethra, and bladder may be followed by calcification and may result in hydroureter, hydronephrosis, and bladder neck obstruction. Renal failure may ultimately develop, and there is a suspicion that squamous cell carcinoma of the bladder may be linked to the chronic infective and inflammatory process. Secondary bacterial infection is common within the obstructed and inflamed urinary tract (254).

The hepatosplenic form of S. mansoni infection may be accompanied by a glomerulopathy in 12–15% of cases, manifested in the majority as nephrotic syndrome (256). Histopathologic findings include mesangioproliferative GN, focal segmental glomerulosclerosis, mesangiocapillary GN, MGN, and focal segmental hyalinosis (257). Immune complexes may be detected in the circulation of these patients, and glomerular granular deposition of IgM, C3, and schistosomal antigens are seen on immunofluorescence. Usually Schistosoma-specific nephropathy is a progressive disease and is not influenced by antiparasitic or immunosuppressive therapy (258), but isolated case reports of remission after treatment with praziquantel have been reported (259).

The diagnosis is confirmed by the detection of Schistosoma eggs in feces, urine, or biopsy specimens. Eggs are shed into the urine with a diurnal rhythm, and urine collected between 11 AM and 1 PM is the most useful. Urinary sediment obtained by centrifugation or filtration through a Nuclepore membrane should be examined.

In cases in which studies of urine and feces yield negative results in patients in whom the diagnosis is suspected, rectal biopsy specimens taken approximately 9 cm from the anus have a high diagnostic yield for both S. mansoni and S. haematobium infection. Biopsy of liver or bladder may be required to establish the diagnosis.

Antibodies indicating previous infection can be detected using enzyme-linked immunosorbent assay or radioimmunoassay. The tests are sensitive but lack specificity and may not differentiate between past exposure and current infection.

Praziquantel is the drug of choice for treatment of schistosomiasis. A single oral dose of 40 mg/kg is effective in S.haematobium and S. mansoni infection and is usually well tolerated. The alternative drug for S. mansoni infection is oxamniquine. Complete remission of urinary symptoms may occur in renal disease of short duration, but in late disease with extensive fibrosis, scarring, and calcification, obstructive uropathy and renal failure may persist after the infection has been eradicated. There are reports of a drastic decrease in the number of severe hepatosplenic forms of S. mansoni infection after mass treatment of the population in endemic areas with oxamniquine. This also reduced schistosomal nephropathy (256).

Leishmaniasis

Visceral leishmaniasis is a chronic protozoon infection characterized by fever, hepatosplenomegaly, anemia, leukopenia, and hyperglobulinemia. Proteinuria and/or microscopic hematuria or pyuria have been reported in 50% of patients with visceral leishmaniasis (260). Acute renal failure in association with interstitial nephritis has also been reported (261). Renal histologic analysis in patients with visceral leishmaniasis reveals glomerular changes, with features of a mesangial proliferative GN or a focal proliferative GN, or a generalized interstitial nephritis with interstitial edema, mononuclear cell infiltration, and focal tubular degeneration. Immunofluorescence reveals deposition of IgG, IgM, and C3 within the glomeruli, as well as electron-dense deposits in the basement membrane and mesangium on electron microscopy (260). Circulating immune complexes together with immunoglobulin and complement deposition in the glomeruli suggests an immune-complex cause.

Renal disease in leishmaniasis is usually mild and may resolve after treatment of the infection. Renal dysfunction may be associated with treatment for visceral leishmaniasis with antimony compounds.

Filariasis

Proteinuria is more common in filarial hyperendemic regions of West Africa than in nonfilarial areas. Renal histologic analysis has shown a variety of different histopathologic appearances; the most common is diffuse mesangial proliferative GN with C3 deposition in the glomeruli (262). Renal biopsy specimens also demonstrate large numbers of eosinophils in the glomeruli, and microfilariae may be seen in the lumen of glomerular capillaries. Filarial antigens have been detected within immune deposits within the glomeruli.

Hydatid Disease

Echinococcus granulosus causes chronic cysts within a variety of organs. In addition, nephrotic syndrome in association with hydatid disease has been reported. Membranous nephropathy, minimal change lesions, and mesangiocapillary GN have been described in association with hydatid disease (263, 264). Immunofluorescence reveals deposits of immunoglobulin, complement, and hydatid antigens within the glomeruli. Remission of nephrotic syndrome has been reported with treatment by antiparasitic agents such as albendazole (263, 264).

Trypanosomiasis

Few reports have been published of renal disease occurring in patients with trypanosomiasis. The trypanosomal antigens can induce GN in a variety of experimental animals (265).

Toxoplasmosis

Nephrotic syndrome has occasionally been reported as a manifestation of congenital toxoplasmosis.

Dissemination of previously latent toxoplasma infection in patients undergoing treatment with immunosuppressive drugs has been increasingly recognized in recent years. Reactivation of toxoplasmosis or progression of recently acquired primary infection should be considered in patients undergoing renal transplantation or immunotherapy for renal disease who develop unexplained inflammation of any organ.

Fungal Infections

Fungal infections of the kidneys and urinary tract occur most commonly as part of systemic fungal infections in patients with underlying immunodeficiency, as focal urinary tract infections in patients with obstructive lesions, or as a result of indwelling catheters. Although Candida infection is the most common fungal infection in both immunocompromised and non immunocompromised hosts, virtually all other fungal pathogens may invade the renal tract during severe immunocompromise.

Urinary infection with Candida albicans is most commonly a component of systemic candidiasis in patients who are severely immunocompromised. Systemic candidiasis is also seen in premature and term infants with perinatally acquired invasive candidiasis. Presentation is usually with systemic sepsis, fever or hypothermia, hepatosplenomegaly, erythematous rash, and thrombocytopenia. Systemic candidiasis may be seen on ophthalmologic investigation as microemboli in the retina. The first clue to the underlying diagnosis may be the presence of yeasts in the urine (266).

Candida involvement of the urinary tract may affect all structures including the glomeruli, tubules, collecting system, ureters, and bladder. Microabscesses may form within the renal parenchyma, and large balls of fungi may completely obstruct the urinary tract at any level. Acute renal failure caused by systemic candidiasis or obstruction of the renal tracts with fungal hyphae is a well-recognized complication of systemic candidal infection (266, 267). Indwelling catheters (which form a nidus for persistent infection) should be removed. Successful treatment of non-obstructing bilateral renal fungal balls by fluconazole either alone or in combination with liposomal amphotericin B has been reported (268, 269). In the presence of obstruction, however, percutaneous nephrostomy to relieve the obstruction with antegrade amphotericin B irrigation, coupled with systemic antifungal therapy, is the mainstay of treatment (267). Amphotericin B is the most effective antifungal agent, but it is not excreted in the urine. Local irrigation via nephrostomy provides good results, however. For treatment of urinary tract candidiasis, it is usually combined with fluconazole or 5-flucytosine, both of which are excreted in high concentrations in the urine. Treatment is required for weeks to months to ensure complete elimination of the fungus, and the ultimate outcome is largely dependent on whether there is a permanent defect in immunity.

Miscellaneous Conditions

Hemorrhagic Shock and Encephalopathy

In 1983, Levin et al. first described hemorrhagic shock and encephalopathy, which appeared to be distinct from previously recognized pediatric disorders (270). Other cases have subsequently been reported from several centers in the United Kingdom, Europe, Israel, the United States, and Australia, and the syndrome is now recognized as a new and relatively common severe childhood disorder (271).

Hemorrhagic shock and encephalopathy usually affects infants in the first year of life, with a peak onset at 3–4 months of age. A prodromal illness with fever, irritability, diarrhea, or upper respiratory infection occurs 2–5 days before the onset in two-thirds of cases. Affected infants develop profound shock, coma, convulsions, bleeding and evidence of DIC, diarrhea, and oliguria. Laboratory findings include acidosis, falling hemoglobin and platelet levels, elevated urea and creatinine levels, and elevated levels of hepatic transaminases. Despite vigorous intensive care, the prognosis is poor, and most affected infants die or are left severely neurologically damaged (271, 272). A small number of patients have been reported to survive without residual sequelae.

The renal impairment appears to be largely prerenal in origin, and when aggressive volume replacement and treatment of the shock results in improved renal perfusion, rapid improvement in renal function is usually observed. In patients with profound shock unresponsive to initial resuscitation, vasomotor nephropathy supervenes and dialysis may be required. Myoglobinuria in association with hemorrhagic shock and encephalopathy has been reported.

Kawasaki Disease

Following the description of the mucocutaneous lymph node syndrome by Kawasaki in 1968, Kawasaki disease has been recognized as a common and serious childhood illness with a worldwide distribution. Although the etiology remains unknown, epidemiologic features clearly suggest an infective cause. The disease occurs in epidemics, and wavelike spread has been demonstrated during outbreaks in Japan.

Amyloidosis

Deposition of amyloid within the kidney is an important complication of chronic and persistent infection. Amyloidosis is most common in patients with chronic osteomyelitis and chronic pulmonary infections such as bronchiectasis and is seen occasionally in those with persistent infections such as leprosy or malaria (273, 274, 275).

References

  1. 1.
    Levin M. Shock. In Paediatric Emergencies, 2nd edn. Black JA (ed.). London, Butterworth, 1987, pp. 87–116.Google Scholar
  2. 2.
    Parkin RM, Levin DL. Shock in the paediatric patient. Pediatr 1982;101:163–169.Google Scholar
  3. 3.
    Cumming AD, Driedgen AA, McDonald JWD et al. Vasoactive hormones in the renal response to systemic sepsis. Am J Kidney Dis 1988;11:23–32.PubMedGoogle Scholar
  4. 4.
    Cohen RI, Hassell AM, Marzouk K et al. Renal effects of nitric oxide in endotoxemia. Am J Respir Crit Care Med 2001;164:1890–1895.PubMedGoogle Scholar
  5. 5.
    Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, Abd-Allah SA, Levy H, Angle R, Wang D et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007;369:836–843.PubMedGoogle Scholar
  6. 6.
    Nadel S, Levin M, Habibi P. Treatment of meningococcal disease in childhood. In Meningococcal Disease. Canwright K (ed.). New York, Wiley, 1995.Google Scholar
  7. 7.
    Heyderman R, Klein N, Levin M. Pathophysiology and management of meningococcal septicaemia. In Recent Advances in Paediatrics, 11th edn. London, Churchill Livingstone, 1993, pp. 1–18.Google Scholar
  8. 8.
    Gedde-Dahl TW, Bjark P, Hoiby EA et al. Severity of meningococcal disease: assessment by factors and scores and implications for patient management. Rev Infect Dis 1990;12:973–991.PubMedGoogle Scholar
  9. 9.
    Case records of the Massachusetts General Hospital. Case 4. N Engl J Med 1988;318:234–242.Google Scholar
  10. 10.
    Brandzaeg P, Kieruif P, Gaustad P et al. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis 1989;159:195–204.Google Scholar
  11. 11.
    Mercier JC, Beaufils F, Hartman JF et al. Hemodynamic patterns of meningococcal shock in children. Crit Care Med 1988;16:27–33.PubMedGoogle Scholar
  12. 12.
    Pathan N, Hemingway CA, Alizadeh AA, Stephens AC, Boldrick JC, Oragui EE, McCabe C, Welch SB, Whitney A, O’Gara P et al. Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet 2004;363:203–209.PubMedGoogle Scholar
  13. 13.
    Faust SN, Levin M, Harrison OB et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001;345:408–416.PubMedGoogle Scholar
  14. 14.
    Faust SN, Levin M, Harrison OB, Goldin RD, Lockhart MS, Kondaveeti S, Laszik Z, Esmon CT, Heyderman RS. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001;345:408–416.PubMedGoogle Scholar
  15. 15.
    Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699–709.PubMedGoogle Scholar
  16. 16.
    Wippermann CF, Schofer O, Beetz R et al. Renal abscess in childhood: diagnostic and therapeutic progress. Pediatr Infect Dis J 1991;10:446–450.PubMedGoogle Scholar
  17. 17.
    Deyoe LA, Cronan JJ, Lambiase RE et al. Percutaneous drainage of renal and perirenal abscesses: results in 30 patients. AJR Am J Roentgenol 1990;155:81–83.PubMedGoogle Scholar
  18. 18.
    Todd J, Fishaut MI, Kaprai F et al. Toxic shock syndrome associated with phage group 1 staphylococci. Lancet 1978;ii:1116–1118.Google Scholar
  19. 19.
    Reingold AL, Shands KL, Dann BB et al. Toxic shock syndrome not associated with menstruation: a review of 54 cases. Lancet 1982;i:l–4.Google Scholar
  20. 20.
    Buchdahl R, Levin M, Willahs B et al. Toxic shock syndrome. Arch Dis Child 1985;60:563–567.PubMedGoogle Scholar
  21. 21.
    Todd JK, Franco-Buf TA, Lowellin DW et al. Phenotypic distinctiveness of Staphylococcus aureus strains associated with toxic shock syndrome. Infect Immun 1984;45:339–344.PubMedGoogle Scholar
  22. 22.
    Marrack P, Kappler J. The staphylococcal enterotoxins and their relatives. Science 1990;248:705–711.PubMedGoogle Scholar
  23. 23.
    Fast DJ, Schlievert PM, Nelson RD. Toxic shock syndrome: associated staphylococcal and streptococcal pyrogenic toxins are potent inducers of tumour necrosis factor. Infect Immun 1989;57:291–294.PubMedGoogle Scholar
  24. 24.
    Toxic shock syndrome. In 2000 Red Book: Report of the Committee on Infectious Diseases, 25th edn. Pickering LK (ed.). Elk Grove Village, IL, American Academy of Pediatrics, 2000, pp. 576–581.Google Scholar
  25. 25.
    Kaneko J, Kamio Y. Bacterial two-component and hetero-heptameric pore-forming cytolytic toxins: structures, pore-forming mechanism, and organization of the genes. Biosci Biotechnol Biochem 2004;68:981–1003.PubMedGoogle Scholar
  26. 26.
    Malik ZA, Litman N. Perinephric abscess caused by community-acquired methicillin resistant Staphylococcus aureus. Pediatr Infect Dis J 2007;26:764.PubMedGoogle Scholar
  27. 27.
    Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ, Bryant AE. Impact of antibiotics on expression of virulence? associated exotoxin genes in methicillin, sensitive and methicillin, resistant Staphylococcus aureus. J Infect Dis 2007;195:202–211.PubMedGoogle Scholar
  28. 28.
    Cone LA, Woodward DR, Schlievert PM et al. Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N Engl J Med 1987;317:146–149.PubMedGoogle Scholar
  29. 29.
    Rodriguez-Iturbe B, Castillo L, Valbuena R. Acute poststreptococcal glomerulonephritis. A review of recent developments. Paediatrician 1979;8:307–324.PubMedGoogle Scholar
  30. 30.
    Dodge WF, Spargo BF, Travis LB. Occurrence of acute glomerulonephritis in sibling contacts of children with sporadic acute glomerulonephritis. Pediatrics 1967;40:1028–1030.PubMedGoogle Scholar
  31. 31.
    Lasch EE, Frankel V, Vardy PA. Epidemic glomerulonephritis in Israel. J Infect Dis 1971;124:141–147.PubMedGoogle Scholar
  32. 32.
    Weinstein L, LeFrock J. Does antimicrobial therapy of streptococcal pharyngitis or pyoderma alter the risk of glomerulonephritis? J Infect Dis 1971;124:229–231.PubMedGoogle Scholar
  33. 33.
    Popovic RM, Kostic M. Medium and long-term prognosis of patients with acute post-streptococcal glomerulonephritis. Nephron 1991;58:393–399.PubMedGoogle Scholar
  34. 34.
    Bamham M, Thornton T, Lange K. Nephritis caused by Streptococcus zooepidemicus (Lancefield group C). Lancet 1983;1:945–948.Google Scholar
  35. 35.
    Gnann JW, Gray BM, Griffin FM et al. Acute glomerulonephritis following group G Streptococcus infection. J Infect Dis 1987;156:411–412.PubMedGoogle Scholar
  36. 36.
    Torres-Martinez C, Mehta D, Butt A et al. Streptococcus associated toxic shock. Arch Dis Child 1992;67:126–130.PubMedGoogle Scholar
  37. 37.
    Stollerman GH. Changing group A Streptococcus: the reappearance of streptococcal “toxic shock.” Arch Intern Med 1988;148:1268–1270.PubMedGoogle Scholar
  38. 38.
    Stevens DL, Tanner MH, Wmship J. Severe group A Streptococcus infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 1989;321:1–7.PubMedGoogle Scholar
  39. 39.
    Edwards RJ, Taylor GW, Ferguson M, Murray S, Rendell N, Wrigley A, Bai Z, Boyle J, Finney SJ, Jones A et al. Specific C-terminal cleavage and inactivation of interleukin-8 by invasive disease isolates of Streptococcus pyogenes. J Infect Dis 2005;192:783–790.PubMedGoogle Scholar
  40. 40.
    Mascini EM, Jansze M, Schouls LM, Verhoef J, Van Dijk H. Penicillin and clindamycin differentially inhibit the production of pyrogenic exotoxins A and B by group A streptococci. Int J Antimicrob Agent 2001;18:395–398.Google Scholar
  41. 41.
    Zimbelman J, Palmer A, Todd J. Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J 1999;18:1096–1100.PubMedGoogle Scholar
  42. 42.
    Darenberg J, Ihendyane N, Sjölin J, Aufwerber E, Haidl S, Follin P, Andersson J, Norrby-Teglund A. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003;37:333–340.PubMedGoogle Scholar
  43. 43.
    Kaul R, McGeer A, Norrby-Teglund A, Kotb M, Schwartz B, O’Rourke K, Talbot J, Low DE. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome – a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis 1999;28:800–807.PubMedGoogle Scholar
  44. 44.
    Zimmerman JJ. A history of adjunctive glucocorticoid treatment for pediatric sepsis: moving beyond steroid pulp fiction toward evidence-based medicine. Pediatr Crit Care Med 2007;8:530–539.PubMedGoogle Scholar
  45. 45.
    Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008;358:125–139.PubMedGoogle Scholar
  46. 46.
    Feigin RD, Anderson DC. Leptospirosis. In Textbook of Paediatric Infectious Diseases, 4th edn. Feigin RD, Cherry JD (eds.). Philadelphia, WB Saunders, 1998, pp. 1529–1542.Google Scholar
  47. 47.
    Lai KN, Aarons I, Woodroffe AJ et al. Renal lesions in leptospirosis. Aust N Z J Med 1982;12:276–279.PubMedGoogle Scholar
  48. 48.
    Kennedy ND, Pusey CD, Rainford DJ et al. Leptospirosis and acute renal failure: clinical experiences and a review of the literature. Postgrad Med J 1979;55:176–179.PubMedGoogle Scholar
  49. 49.
    Clerke AM, Leuva AC, Joshi C et al. Clinical profile of leptospirosis in South gujarat. J Postgrad Med 2002;48:I17–118.Google Scholar
  50. 50.
    De Francesco Daher E, Oliveira Neto FH, Ramirez SM. Evaluation of hemostasis disorders and anticardiolipin antibody in patients with severe leptospirosis. Rev Inst Med Trop Sao Paulo 2002;44:85–90.PubMedGoogle Scholar
  51. 51.
    Watt G, Tuazon ML, Santiago E. Placebo controlled trial of intravenous penicillin for severe and late leptospirosis. Lancet 1988;1:433–435.PubMedGoogle Scholar
  52. 52.
    Gasser VC, Gautier E, Steck A et al. Hämolytich-urämiche Syndrome: bilaterale Nierenrindennekrosen bei akuten erworbenen hämolytischen Anämien. Schweiz Med Wochenschr 1955;85:905.PubMedGoogle Scholar
  53. 53.
    Seger R, Joller P, Baeriocher K. Hemolytic-uremic syndrome associated with neuraminidase-producing micro-organism: treatment by exchange transfusion. Helv Paediatr Acta 1980;35:359–367.PubMedGoogle Scholar
  54. 54.
    Moorthy B, Makker SE. Hemolytic uremic syndrome associated with pneumococcal sepsis. J Pediatr 1979;95:558–559.PubMedGoogle Scholar
  55. 55.
    Kaplan BS, Cleary TG, Obrig TG. Recent advances in understanding the pathogenesis of the hemolytic uremic syndromes. Pediatr Nephrol 1990;4:276–283.PubMedGoogle Scholar
  56. 56.
    Schenk EA, Panke TW Cole HA. Glomerular and arteriolar thrombosis in pneumococcal septicemia. Arch Pathol 1970;89:154–159.PubMedGoogle Scholar
  57. 57.
    Cabrera GR, Forrenberry JD, Warshaw BL et al. Hemolytic uremic syndrome associated with invasive Streptococcus pneumoniae infection. Pediatrics 1998;101:699–703.PubMedGoogle Scholar
  58. 58.
    Seger R, Joller P, Baeriocher K et al. Hemolytic-uremic syndrome associated with neuraminidase-producing microorganisms: treatment by exchange transfusion. Helv Paediatr Acta 1980;35:359–367.PubMedGoogle Scholar
  59. 59.
    Eber SW, Polster H, Quentin SH et al. Hämolytisch-urämisches Syndrome bei pneumokok-ken-menigitis und -sepsis. Bedeutung der T-transformation. Monatsschr Kinderheilkd 1993;141:219–222.PubMedGoogle Scholar
  60. 60.
    Nathanson S, Deschenes G. Prognosis of Streptococcus pneumoniae-induced hemolytic uremic syndrome. Pediatr Nephrol 2001;16:362–365.PubMedGoogle Scholar
  61. 61.
    Brandt J, Wong C, Mihm S et al. Invasive pneumococcal disease and hemolytic uremic syndrome. Pediatrics 2002;110:37L-–376.Google Scholar
  62. 62.
    Waters AM, Kerecuk L, Luk D, Haq MR, Fitzpatrick MM, Gilbert RD, Inward C, Jones C, Pichon B, Reid C et al. Hemolytic uremic syndrome associated with invasive pneumococcal disease: the United kingdom experience. J Pediatr 2007;151:140–144.PubMedGoogle Scholar
  63. 63.
    Beaufils M, Morel Maroger L, Sraer JD et al. Acute renal failure of glomerular origin during visceral abscess. N Engl J Med 1976;295:185–189.PubMedGoogle Scholar
  64. 64.
    Sitprija V, Pipatanagul V, Boonpucknavig V et al. Glomerulitis in typhoid fever. Ann Intern Med 1974;81:210–213.PubMedGoogle Scholar
  65. 65.
    Awunor-Renner C, Lawande RV. Yersinia and chronic glomerulopathy in the Savannah region of Nigeria. BMJ 1982;285:1464.PubMedGoogle Scholar
  66. 66.
    Buka I, Coovadia HM. Typhoid glomerulonephritis. Arch Dis Child 1980;55:305–307.PubMedGoogle Scholar
  67. 67.
    Dhawan A, Marwaha RK. Acute glomerulonephritis in multi-drug resistant Salmonella typhi infection. Indian Pediatr 1992;29:1039–1041.PubMedGoogle Scholar
  68. 68.
    Srivastava RN. Acute glomerulonephritis in Salmonella typhi infection. Indian Pediatr 1993;30:278–279.PubMedGoogle Scholar
  69. 69.
    Korpela M, Mustonen J, Pasternack A et al. Urinary tract and renal findings in acute Yersinia infection. Acta Med Scand 1986;220:471–476.PubMedGoogle Scholar
  70. 70.
    Fukumoto Y, Hiraoka M, Takano T et al. Acute tubulointerstitial nephritis in association with Yersinia pseudotuberculosis infection. Pediatr Nephrol 1995;9:78–80.PubMedGoogle Scholar
  71. 71.
    Koo JW, Park SN, Choi SM et al. Acute renal failure associated with Yersinia pseudotuberculosis infection in children. Pediatr Nephrol 1996;10:582–586.PubMedGoogle Scholar
  72. 72.
    Cheong HI, Choi EH, Ha IS et al. Acute renal failure associated with Yersinia pseudotuberculosis infection. Nephron 1995;70:319–323.PubMedGoogle Scholar
  73. 73.
    Sato K, Oucfii K, Komazawa M. Ampicillin vs. placebo for Yersinia pseudotuberculosis infection in children. Pediatr Infect Dis J 1988;7:686–689.PubMedGoogle Scholar
  74. 74.
    Yersinia enterocolitica and Yersinia pseudotuberculosis infections. In 2000 Red Book: Report of the Committee on Infectious Diseases, 25th edn. Pickering LK (ed.). Elk Grove Village, IL: American Academy of Pediatrics, 2000, pp. 642–643.Google Scholar
  75. 75.
    Karmali MA, Petric M, Steele BT. Sporadic cases of haemolytic uraemic syndrome associated with faecal cytotoxin and cyto-toxin producing Escherichia coli in stools. Lancet 1983;1:619–620.PubMedGoogle Scholar
  76. 76.
    World Health Organization, Tuberculosis, Fact Sheet No. 104. Revised. Geneva: World Health Organization, August 2002.Google Scholar
  77. 77.
    Dye C, Scheele S, Dolin P et al. for the WHO Global Surveillance and Monitoring Project. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA 1999;282:677–686.PubMedGoogle Scholar
  78. 78.
    Des Pres RM, Heim CR. Mycobacterium Tuberculosis. In Principles and practice of infectious diseases, 3rd edn. Mandell GL, Douglas RG, Bennert JE (eds.). London, Churchill Livingstone, 1990, pp. 1877–1906.Google Scholar
  79. 79.
    Cos LR, Cockett AT. Genitourinary tuberculosis revisited. Urology 1982;20:111–117.PubMedGoogle Scholar
  80. 80.
    Ehrlich RM, Lattimen J. Urogenital tuberculosis in children. J Urol 1971;105:461–465.PubMedGoogle Scholar
  81. 81.
    Christensen WI. Genitourinary tuberculosis: review of 102 cases. Medicine 1974;53:377–390.PubMedGoogle Scholar
  82. 82.
    Kaplan BS, Wiglesworth FW, Marks ML. The glomerulopathy of congenital syphilis: an immune deposit disease. J Pediatr 1972;81:1154–1156.PubMedGoogle Scholar
  83. 83.
    Bhorades MS, Caray HB, Lee HJ. Nephropathy of secondary syphilis: a clinical and padiological spectrum. JAMA 1971;216:1159–1166.Google Scholar
  84. 84.
    Gamble CN, Reardan JB. Immunopathogenesis of syphilitic glomerulonephritis. N Engl J Med 1975;292:449–454.PubMedGoogle Scholar
  85. 85.
    Cochat P, Colon S, Bosshatd S et al. Membranoproliferative glomerulonephritis and Mycoplasma pneumoniae infection. Arch Fr Pediatr 1985;42:29–31.PubMedGoogle Scholar
  86. 86.
    Vitullo BB, O’Regan S, De Chadaneuian JE. Mycoplasma pneumoniae associated with acute glomerulonephritis. Nephron 1978;21:284–287.PubMedGoogle Scholar
  87. 87.
    Said MH, Layani MP, Colon S et al. Mycoplasma pneumoniae-associated nephritis in children. Pediatr Nephrol 1999;13:39–44.PubMedGoogle Scholar
  88. 88.
    Edwards MS, Feigin RD. Rickettsial Disease. In Textbook of Pediatric Infectious Diseases, 4th edn. Feigin RD, Cherry JD (eds.). Philadelphia, WB Saunders, 1998, pp. 2239–2258.Google Scholar
  89. 89.
    Heimick CG, Bernard KW, Dangelo LJ. Rocky Mountain spotted fever: clinical, laboratory and epidemiological features in 262 cases. J Infect Dis 1984;150:480–486.Google Scholar
  90. 90.
    Walker DH, Mattern WD. Acute renal failure in Rocky Mountain spotted fever. Arch Intern Med 1979;139:443–448.PubMedGoogle Scholar
  91. 91.
    Bradford WD, Croker BP, Tisher CL. Kidney lesion in Rocky Mountain spotted fever. Am J Pathol 1979;97:381–392.PubMedGoogle Scholar
  92. 92.
    Quigg RJ, Gaines R, Wakely PE Jr et al. Acute glomerulonephritis in a patient with Rocky Mountain spotted fever. Am J Kidney Dis 1991;17:339–342.PubMedGoogle Scholar
  93. 93.
    Dimmit SK, Millen DK. Rocky Mountain spotted fever. Am J Clin Pathol 1982;78:131–134.Google Scholar
  94. 94.
    Rocky Mountain spotted fever. In 2000 Red Book: Report of the Committee on Infectious Diseases, 25th edn. Pickering LK (ed.). Elk Grove Village, IL: American Academy of Pediatrics, 2000, pp. 491–493.Google Scholar
  95. 95.
    Sawyer LA, Fishbein DB, McDade JE. Q fever: current concepts. Rev Infect Dis 1987;9:935–946.PubMedGoogle Scholar
  96. 96.
    Dathan JRE, Heyworth MF. Glomerulonephritis associated with Coxiella burnetii endocarditis. BMJ 1975; L376.Google Scholar
  97. 97.
    Cutz E, Thonner PS, Raoc P. Disseminated Legionella pneumophila infection in an infant with severe combined immunodeficiency. J Pediatr 1982;100:760–762.PubMedGoogle Scholar
  98. 98.
    Shah A, Check F, Baskin S et al. Legionnaire’s disease and acute renal failure: base report and review. Clin Infect Dis 1992;14:204–207.PubMedGoogle Scholar
  99. 99.
    Nishitarumizu K, Tokuda Y, Uehara H et al. Tubulointerstitial nephritis associated with Legionnaires’ disease. Intern Med 2000;39(2):150–153.PubMedGoogle Scholar
  100. 100.
    Gutman RA, Striker GE, Gililand BC. The immune complex glomerulonephritis of bacterial endocarditis. Medicine 1972;51:1–5.PubMedGoogle Scholar
  101. 101.
    Perez-Fontan M, Huarte E, Tellez A et al. Glomerular nephropathy associated with chronic Q fever. Am J Kidney Dis 1988;4:298–306.Google Scholar
  102. 102.
    Tompkins LS, Roessler BJ, Redd SC et al. Legionella prosthetic-valve endocarditis. N Engl J Med 1988;318:530–535.PubMedGoogle Scholar
  103. 103.
    Neugarten N, Baldwin DS. Glomerulonephritis in bacterial endocarditis. Am J Med 1984;77:297–304.PubMedGoogle Scholar
  104. 104.
    Levy RL, Hong R. The immune nature of subacute bacterial endocarditis (SBE) nephritis. Am J Med 1973;54:645–652.PubMedGoogle Scholar
  105. 105.
    Baltimore RS. Infective endocarditis in children. Pediatr Infect Dis J 1992;11:903–907Google Scholar
  106. 106.
    Haffher , DSchlndera F, Aschoff A et al. The clinical spectrum of shunt nephritis. Nephrol Dial Transplant 1997;12:1143–1148.Google Scholar
  107. 107.
    Dobrin RS, Day NK, Quie PG et al. The role of complement, immunoglobulin and bacterial antigen in coagulase-negative staphylococcal shunt nephritis. Am J Med 1975;59:660–073.PubMedGoogle Scholar
  108. 108.
    Zunin C, Castellani A, Olivetti G et al. Membranoproliferative glomerulonephritis associated with infected ventriculoatrial shunt: report of two cases recovered after removal of the shunt. Pathologica 1977;69:297–305.PubMedGoogle Scholar
  109. 109.
    Tiollais P, Pourcel C, Dejean A. The hepatitis B virus. Nature 1985;317:489–495.PubMedGoogle Scholar
  110. 110.
    Johnson RJ, Couser WG. Hepatitis B infection and renal disease: clinical, immunopathogenetic and therapeutic considerations. Kidney Int 1990;37:663–676.PubMedGoogle Scholar
  111. 111.
    Gocke DJ. Extrahepatic manifestations of viral hepatitis. Am J Med Sci 1975;270:49–52.PubMedGoogle Scholar
  112. 112.
    Sergent JS, Lockshin MD, Christian CL Vasculitis with hepatitis B antigenemia. Long term observation in nine patients. Medicine 1976;55:1–17.PubMedGoogle Scholar
  113. 113.
    Reznik VM, Mendoza SA, Self TW et al. Hepatitis B-associated vasculitis in an infant. J Pediatr 1981;98:252–254.PubMedGoogle Scholar
  114. 114.
    Guillevin L, Lhote F, Cohen P, Sauvaget F, Jarrousse B, Lortholary O, Noël LH, Trépo C. Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine 1995;74:238–253.PubMedGoogle Scholar
  115. 115.
    Guillevin L, Mahr A, Callard P, Godmer P, Pagnoux C, Leray E, Cohen P. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine 2005;84:313–322.PubMedGoogle Scholar
  116. 116.
    Michalak T. Immune complexes of heparins B surface antigen in the pathogenesis of periarteritis nodosa. A study of seven necropsy cases. Am J Pathol 1978;90:619–632.PubMedGoogle Scholar
  117. 117.
    Avsar E, Savas B, Tozun N et al. Successful treatment of polyarteritis nodosa related to hepatitis B virus with interferon alpha as first-line therapy. J Hepatol 1998;28:525–526.PubMedGoogle Scholar
  118. 118.
    Gupta S, Piraka C, Jaffe M. Lamivudine in the treatment of polyarteritis nodosa associated with acute hepatitis B. N Engl J Med 2001;344:1645–1646.PubMedGoogle Scholar
  119. 119.
    Erhardt A, Sagir A, Guillevin L et al. Successful treatment of hepatitis B virus associated polyarteritis nodosa with a combination of prednisolone, afpha-interferon and Iamivudine. J Hepatol 2000;33:677–683.PubMedGoogle Scholar
  120. 120.
    Wiggelinkhuizen J, Sinclair SC. Membranous glomerulonephropathy in childhood. S Afr Med J 1987;72:184–187.PubMedGoogle Scholar
  121. 121.
    Southwest Pediatric Nephrology Study Group. Hepatitis B surface antigenemia in North American children with membranous glomerlonephropathy. J Pediatr 985;106:571–577.Google Scholar
  122. 122.
    Lai KN, Lai FM. The clinico-pathologic features of hepatitis B virus-associated glomerulonephritis. QJM 1987;63:323–333.PubMedGoogle Scholar
  123. 123.
    Ren J, Wang L, Chen Z, Ma ZM, Zhu HG, Yang DL, Li XY, Wang BI, Fei J, Wang ZG et al. Gene expression profile of transgenic mouse kidney reveals pathogenesis of hepatitis B virus associated nephropathy. J Med Virol 2006;78:551–560.PubMedGoogle Scholar
  124. 124.
    Ozdamar SO, Gucer S, Tinaztepe K. Hepatitis-B virus associated nephropathies: a clinicopathological study in 14 children. Pediatr Nephrol 2003;18:23–28.PubMedGoogle Scholar
  125. 125.
    Lai KN, Lai FM. Strong association between IgA nephropathy and hepatitis B surface antigenemia in endemic areas. Clin Nephrol 1988;29:229–234.PubMedGoogle Scholar
  126. 126.
    Thomas HC, Lever AML, Scully LJ et al. Approaches to the treatment of hepatitis B virus and delta-related liver disease. Semin Liver Dis 1986;6:34–40.PubMedGoogle Scholar
  127. 127.
    Connor FL, Rosenberg AR, Kennedy SE, Bohane TD. HBV associated nephrotic syndrome: resolution with oral lamivudine. Arch Dis Child 2003;88:446–449.PubMedGoogle Scholar
  128. 128.
    Farrell GC, Teoh NC. Management of chronic hepatitis B virus infection: a new era of disease control. Intern Med J 2006;36:100–113.PubMedGoogle Scholar
  129. 129.
    Izzedine H, Massard J, Poynard T, Deray G. Lamivudine and HBV-associated nephropathy. Nephrol Dial Transplant 2006;21:828–829.PubMedGoogle Scholar
  130. 130.
    Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705–714.PubMedGoogle Scholar
  131. 131.
    Jonas MM. Children with hepatitis C. Hepatology 2002;36:S173–S178.PubMedGoogle Scholar
  132. 132.
    Stehman-Breen C, Willson R, Alpers CE et al. Hepatitis C virus-associated glomerulonephritis. Curr Opin Nephrol Hypertens 1995;4:287–294.PubMedGoogle Scholar
  133. 133.
    Stehman-Bteen C, Aipers CE, Fleet WP et al. Focal segmental glomerular sclerosis among patients infected with hepatitis C virus. Nephron 1999;81:37–40.Google Scholar
  134. 134.
    Johnson RJ, Gretch DR, Couser WG et al. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int 1994;46:1700–1704.PubMedGoogle Scholar
  135. 135.
    Sabry AA, Sobh MA, Irving WL et al. A comprehensive study of the association between hepatitis C virus and glomerulopathy. Nephrol Dial Transplant 2002;17:239–245.PubMedGoogle Scholar
  136. 136.
    Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002;36:3–10.PubMedGoogle Scholar
  137. 137.
    Molle ZL, Baqi N, Gretch D et al. Hepatitis C infection in children and adolescents with end-stage renal disease. Pediatr Nephrol 2002;17:444–449.PubMedGoogle Scholar
  138. 138.
    Batty DS Jr, Swanson SJ, Kirk AD et al. Hepatitis C virus seropositivity at the time of renal transplantation in the United States: associated factors and patient survival. Am J Transplant 2001;1:179–184.PubMedGoogle Scholar
  139. 139.
    Roth D, Cirocco R, Zucker K et al. De novo membranoproliferative glomerulonephritis in hepatitis C virus-infected renal allograft recipients. Transplantation 1995;59:1676–1682.PubMedGoogle Scholar
  140. 140.
    Cruzado JM, Carrera M, Torras J et al. Hepatitis C virus infection and de novo glomerular lesions in renal allografts. Am J Transplant 2001;1:171–178.PubMedGoogle Scholar
  141. 141.
    Murray KF, Rodrigue JR, Gonzalez-Peralta RP, Shepherd J, Barton BA, Robuck PR, Schwarz KB for the P-CCRN. Design of the PEDS-C trial: pegylated interferon +/−ribavirin for children with chronic hepatitis C viral infection. Clin Trials 2007;4:661–673.PubMedGoogle Scholar
  142. 142.
    Sabry AA, Sobh MA, Sheaashaa HA et al. Effect of combination therapy (ribavirin and interferon) in HCV-related glomerulopathy. Nephrol Dial Transplant 2002;17:1924–1930.for the P-CCRN.PubMedGoogle Scholar
  143. 143.
    Rostaing L, Modesto A, Baron E et al. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 1996;74:512–516.PubMedGoogle Scholar
  144. 144.
    Beuthien W, Mellinghoff HU, Kempis J. Vasculitic complications of interferon-alpha treatment for chronic hepatitis C virus infection: case report and review of the literature. Clin Rheumatol 2005;24:507–515.PubMedGoogle Scholar
  145. 145.
    Myerson D, Hackman RC, Nelson JA et al. Widespread presence of histologically occult cytomegalovirus. Hum Pathol 1984;15:430–439.PubMedGoogle Scholar
  146. 146.
    Beneck D, Greco MA, Feinder HD. Glomerulonephritis in congenital cytomegalic inclusion disease. Hum Pathol 1986;17:1054–1059.PubMedGoogle Scholar
  147. 147.
    Stagno S, Volanakis JE, Reynolds DW et al. Immune complexes in congenital and natal cytomegalovirus infection of man. Clin Invest 1977;60:838–845.Google Scholar
  148. 148.
    Richardson WP, Colvin RB, Cheeseman SH et al. Glomerulopathy associated with cytomegalovirus virenmia in renal allografts. N Engl J Med 1981;305:57–63.PubMedGoogle Scholar
  149. 149.
    Breinig MK, Zitelli B, Starzl TE et al. Epstein-Barr virus, cytomegalovirus and other viral infections in children after transplant. J Infect Dis 1999;156:273–279.Google Scholar
  150. 150.
    Onuigbo M, Haririan A, Ramos E et al. Cytomegalovirus-induced glomerular vasculopathy in renal allografts: a report of two cases. Am J Transplant 2002;2:684–688.PubMedGoogle Scholar
  151. 151.
    Tong CY, Bakran A, Peiris JS et al. The association of viral infection and chronic allograft: nephropathy with graft dysfunction after renal transplantation. Transplantation 2002;74:576–578.PubMedGoogle Scholar
  152. 152.
    Hodson EM, Craig JC, Strippoli GF, Webster AC. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2008;16:CD003774.Google Scholar
  153. 153.
    Fishman JA, Rubin RH. Infection in organ transplant recipients. N Engl J Med 1998;338:1741–1751.PubMedGoogle Scholar
  154. 154.
    Minkowitz S, Wenk R, Friedman E et al. Acute glomerulonephritis associated with varicella infection. Am J Med 1968;44:489–92.PubMedGoogle Scholar
  155. 155.
    Os I, Srrom EH, Stenehjem A et al. Varicella infection in a renal transplant recipient associated with abdominal pain, hepatitis, and glomerulonephritis. Scand J Urol Nephrol 2001;35:330–333.PubMedGoogle Scholar
  156. 156.
    Lin CY, Hsu HC, Hung HY. Nephrotic syndrome associated with varicella infection. Pediatrics 1985;75:1127–1131.PubMedGoogle Scholar
  157. 157.
    Cataudella JA, Young ID, Iliescu EA. Epstein-Barr virus-associated acute interstitial nephritis: infection or immunologic phenomenon? Nephron 2002;92:437–439.PubMedGoogle Scholar
  158. 158.
    Verma N, Arunabh S, Brady TM et al. Acute interstitial nephritis secondary to infectious mononucleosis. Clin Nephrol 2002;58:151–154.PubMedGoogle Scholar
  159. 159.
    Okada H, Ikeda N, Kobayashi T et al. An atypical pattern of Epstein-Barr virus infection in a case with idiopathic tubulointerstitial nephritis. Nephron 2002;92:440–444.PubMedGoogle Scholar
  160. 160.
    Sinniah R, Khan TN, Dodd S. An in situ hybridization study of herpes simplex and Epstein Barr viruses in IgA nephropathy and non-immune glomerulonephritis. Clin Nephrol 1993;40:137–141.PubMedGoogle Scholar
  161. 161.
    Mufson MA, Belshe RB. A review of adenoviruses in the aetiology of haemorrhagic cystitis. Urol 1976;115:191–194.Google Scholar
  162. 162.
    Pasch A, Frey FJ. Coxsackie B viruses and the kidney – a neglected topic. Nephrol Dial Transplant 2006;21:1184–1187.PubMedGoogle Scholar
  163. 163.
    Lin CY, Hsu HC. Measles and acute glomerulonephritis. Pediatrics 1983;17:398–401.Google Scholar
  164. 164.
    Lin CY, Chen WP, Chiang H. Mumps associated with nephritis. Child Nephrol Urol 1990;10:68–71.PubMedGoogle Scholar
  165. 165.
    Rao TKS, Filippone EJ, Nicastri AD et al. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med 1984;310:669–673.PubMedGoogle Scholar
  166. 166.
    Gardenswartz MH, Lerner CW, Seligson GR et al. Renal disease in patients with AIDS: a clinicopathologic study. Clin Nephrol 1984;21:197–204.PubMedGoogle Scholar
  167. 167.
    Patdo V, Aldana M, Colton RM et al. Glomerular lesions in the acquired immunodeficiency syndrome. Ann Intern Med 1984;101:429–434.Google Scholar
  168. 168.
    Strauss J, Montane B, Scott G et al. Urinary and renal histological changes in children with the acquired immunodeficiency syndrome (AIDS). Pediatr Res 1984;18:371A.Google Scholar
  169. 169.
    Ingulli E, Tejani A, Fikrig S et al. Nephrotic syndrome associated with acquired immunodeficiency syndrome in children. J Pediatr 1991;119:710–716.PubMedGoogle Scholar
  170. 170.
    Strauss J, Zilleruelo G, Abitbol C et al. Human immunodeficiency virus nephropathy. Pediatr Nephrol 1993;7:220–225.PubMedGoogle Scholar
  171. 171.
    Ray PE, Rakusan T, Loechelt BJ et al. Human immunodeficiency virus (HIV)-associated nephropathy in children from the Washington, D.C. area: 12 years’ experience. Semin Nephrol 1998;18:396–405.PubMedGoogle Scholar
  172. 172.
    Wyatt CM, Klotman PE. HIV-1 and HIV-associated nephropathy 25 years later. Clin J Am Soc Nephrol 2007;2:S20–S24.PubMedGoogle Scholar
  173. 173.
    D’Agati V, Appel GB. Renal pathology of human immunodeficiency virus infection. Semin Nephrol 1998;18:406–421.PubMedGoogle Scholar
  174. 174.
    Dellow E, Unwin R, Miller R et al. Protease inhibitor therapy for HIV infection: the effect on HIV-associated nephrotic syndrome. Nephrol Dial Transplant 1999;14:744–747.PubMedGoogle Scholar
  175. 175.
    Nebuloni M, Tosoni A, Boldorini R et al. BK virus renal infection in a patient with the acquired immunodeficiency syndrome. Arch Pathol Lab Med 1999;123:807–811.PubMedGoogle Scholar
  176. 176.
    Kopp JB, Falloon J, Filie A et al. Indinavir-associated interstitial nephritis and urothelial inflammation: clinical and cytologic findings. Clin Infect Dis 2002;34:1122–1128.PubMedGoogle Scholar
  177. 177.
    Dimitrakopoulos AN, Kordossis T, Hatzakis A et al. Mixed cryoglobulinemia in HIV-1 infection: the role of HIV-1. Ann Intern Med 1999;130:226–230.PubMedGoogle Scholar
  178. 178.
    Turner ME, Kher K, Rakusan T et al. A typical hemolytic uremic syndrome in human immunodeficiency virus-1- infected children. Pediatr Nephrol 1997;11:161–163.PubMedGoogle Scholar
  179. 179.
    Winston JA, Klotman ME, Klotman PE. HIV-associated nephropathy is a late, not early, manifestation of HIV-1 infection. Kidney Int 1999;55:1036–1040.PubMedGoogle Scholar
  180. 180.
    Cohen AH. HIV-associated nephropathy: current concepts. Nephrol Dial Transplant 1998;13:540–542.PubMedGoogle Scholar
  181. 181.
    Cohen AH, Cohen GM. HIV-associated nephropathy. Nephron 1999;83:111–116.PubMedGoogle Scholar
  182. 182.
    Kajiyama W, Kopp JB, Marinos NJ et al. Glomerulosclerosis and viral gene expression in HIV-transgenic mice: role of nef. Kidney Int 2000;58:1148–1159.PubMedGoogle Scholar
  183. 183.
    Schwartz EJ, Klotman PE. Pathogenesis of human immunodeficiency virus (HIV)-associated nephropathy. Semin Nephrol 1998;18:436–445.PubMedGoogle Scholar
  184. 184.
    Yamamoto T, Noble NA, Miller DE et al. Increased levels of transforming growth factor-[beta] in HIV-associated nephropathy. Kidney Int 1999;55:579–592.PubMedGoogle Scholar
  185. 185.
    Appel RG, Neil! J. A steroid responsive nephrotic syndrome in a patient with human immunodeficiency virus infection. Ann Intern Med 1990;113:892–895.PubMedGoogle Scholar
  186. 186.
    Briggs WA, Tanawattanacharoen S, Choi MJ et al. Clinicopathologic correlates of prednisone treatment of human immunodeficiency virus-associated nephropathy. Am J Kidney Dis 1996;28:618–621.PubMedGoogle Scholar
  187. 187.
    Eustace JA, Nuermberger E, Choi M et al. Cohort study of the treatment of severe HFV-associated nephropathy with corticosteroids. Kidney Int 2000;58:1253–1260.PubMedGoogle Scholar
  188. 188.
    Smith MC, Austen JL, Carey JT et al. Prednisone improves renal function and proteinuria in human immunodeficiency virus-associated nephropathy. Am J Med 1996;101:41–48.PubMedGoogle Scholar
  189. 189.
    Burns GC, Paul SK, Toth IR et al. Effect of angiotensin-converting enzyme inhibition in HIV-associated nephropathy. J Am Soc Nephrol 1997;8:1140–1146.PubMedGoogle Scholar
  190. 190.
    Morales E, Martinez A, Sanchez-Ayuso J et al. Spontaneous improvement of the renal function in a patient with HIV-associated focal glomerulosclerosis. Am J Nephrol 2002;22:369–371.PubMedGoogle Scholar
  191. 191.
    Wüi RK, Drachenberg CI, Papadimitrou JC et al. HIV-1-associared nephropathy and response to highly-active antiretroviral therapy. Lancet 1998;352:783–784.Google Scholar
  192. 192.
    Dellow E, Unwin R, Miller R et al. Protease inhibitor therapy for HIV infection: the effect on HIV-associated nephrotic syndrome. Nephrol Dial Transplant 1999;14:744–747.PubMedGoogle Scholar
  193. 193.
    Ifudu O, Rao TK, Tan CC et al. Zidovudine is beneficial in human immunodeficiency virus associated nephropathy. Am J Nephrol 1995;15:217–221.PubMedGoogle Scholar
  194. 194.
    Ross MJ, Fan C, Ross MD, Chu T-H, Shi Y, Kaufman L, Zhang W, Klotman ME, Klotman PE. HIV-1 infection initiates an inflammatory cascade in human renal tubular epithelial cells. J Acquir Immune Defic Syndr 2006;42:1–11.PubMedGoogle Scholar
  195. 195.
    Kimmel PL, Bosch JP, Vassalotti JA. Treatment of human immunodeficiency virus (HIV)-associated nephropathy. Semin Nephrol 1998;18:446–458.PubMedGoogle Scholar
  196. 196.
    Abbott KC, Trespalacios FC, Agodoa LY, Ahuja TS. HIVAN and medication use in chronic dialysis patients in the United States: analysis of the USRDS DMMS Wave 2 study. BMC nephrol 2003;4:5.PubMedGoogle Scholar
  197. 197.
    Dave MB, Shabih K, Blum S. Maintenance hemodialysis in patients with HIV-associated nephropathy. Clin Nephrol 1998;50:367–374.PubMedGoogle Scholar
  198. 198.
    HIV + Solid Organ Transplant Multi-Site Study. Clinical, immunologic and pharmacologic consequences of kidney transplantation in people with HIV infection. Available : http://spithre.ernmes.com/study/hiv-k/. Accessed December 2002.
  199. 199.
    Roland ME, Barin B, Carlson L, Frassetto LA, Terrault NA, Hirose R, Freise CE, Benet LZ, Ascher NL, Roberts JP et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant 2008;8:355–365.PubMedGoogle Scholar
  200. 200.
    Gardner SD, Field AM, Coleman DV et al. New human papovavirus (BK) isolated from urine after renal transplantation. Lancet 1971;1:1253–1257.PubMedGoogle Scholar
  201. 201.
    Binet I, Nickeleit V, Hirsch HH et al. Polyomavirus disease under new immunosuppressive drugs: a cause of renal graft dysfunction and graft loss. Transplantation 1999;67:918–922.PubMedGoogle Scholar
  202. 202.
    Howell DN, Smith SR, Butterly DW et al. Diagnosis and management of BK Polyomavirus interstitial nephritis in renal transplant recipients. Transplantation 1999;68:1279–1288.PubMedGoogle Scholar
  203. 203.
    Nickeleit V, Hirsch HH, Binet IF et al. Polyomavirus infection of renal allograft recipients: from latent infection to manifest disease. J Am Soc Nephrol 1999;10:1080–1089.PubMedGoogle Scholar
  204. 204.
    Nickeleic Y, KlimkaitT, Binet IF et al. Testing for Polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy. N Engl J Med 2000;342:1309–1315.Google Scholar
  205. 205.
    Randhawa PS, Demetris AJ. Nephropathy due to Polyomavirus type BK. N Engl J Med 2000;342:1361–1363.PubMedGoogle Scholar
  206. 206.
    Drachenberg CB, Papadimitriou JC. Polyomavirus-associated nephropathy: update in diagnosis. Transpl Infect Dis 2006;8:68–75.PubMedGoogle Scholar
  207. 207.
    Kwak EJ, Vilchez RA, Randhawa P et al. Pathogenesis and management of Polyomavirus infection in transplant recipients. Clin Infect Dis 2002;35:1081–1087.PubMedGoogle Scholar
  208. 208.
    Lin PL, Vats AN, Green M. BK virus infection in renal transplant recipients. Pediatr Transplant 2001;5:398–405.PubMedGoogle Scholar
  209. 209.
    Hirsch HH, Knowles W, Dickenmann M et al. Prospective study of Polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002;347:488–496.PubMedGoogle Scholar
  210. 210.
    Acott PD, Hirsch HH. BK virus infection, replication, and diseases in pediatric kidney transplantation. Pediatr Nephrol 2007;22:1243–1250.PubMedGoogle Scholar
  211. 211.
    Arthur RR, Shah KV. Occurrence and significance of papovaviruses BK and JC in the urine. Prog Med Virol 1989;36:44–61.Google Scholar
  212. 212.
    Mathur VS, Olson JL, Darragh TM et al. Polyoma-virus induced interstitial nephritis in two renal transplant recipients: case reports and review of the literature. Am J Kidney Dis 1997;29:754–758.PubMedGoogle Scholar
  213. 213.
    Apperley JF, Rice SJ, Bishop JA et al. Late-onset hemorrhagic cystitis associated with urinary excretion of polyoma-viruses after bone marrow transplantation. Transplantation 1987;43:108–112.PubMedGoogle Scholar
  214. 214.
    Emerson LL, Carney HM, Layfield LJ, Sherbotie JR. Collecting duct carcinoma arising in association with BK nephropathy post-transplantation in a pediatric patient. A case report with immunohistochemical and in situ hybridization study. Pediatr Transplant 2008;12:600–605.PubMedGoogle Scholar
  215. 215.
    Kausman.Association of renal adenocarcinoma and bk virus nephropathy post-transplantation. Pediatr Nephrol 2004;19:459.PubMedGoogle Scholar
  216. 216.
    Ramos E, Drachenberg CB, Papadimitriou JC et al. Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol 2002;13:2145–2151.PubMedGoogle Scholar
  217. 217.
    LeDuc JW. Epidemiology of haemorrhagic fever viruses. Rev Infect Dis 1989;11:5730–5735.Google Scholar
  218. 218.
    Cosgrif FTM. Virus and hemostasis. Rev Infect Dis 1989;11:S677–S688.Google Scholar
  219. 219.
    Hayes EB, Gubler DJ. Dengue and dengue haemorrhagic fever. Pediatr Infect Dis 1992;11:311–317.Google Scholar
  220. 220.
    Boonpucknavig V, Bhamarapravati N, Boonpucknavtg S et al. Glomerular changes in dengue haemorrhagic fever. Arch Pathol Lab Med 1976;100:206–212.PubMedGoogle Scholar
  221. 221.
    Molyneux EM, Maitland K. Intravenous fluids – getting the balance right. N Engl J Med 2005;353:941–944.PubMedGoogle Scholar
  222. 222.
    Wills BA, Nguyen MD, Ha TL, Dong TH, Tran TN, Le TT, Tran VD, Nguyen TH, Nguyen VC, Stepniewska K et al. Comparison of three fluid solutions for resuscitation in dengue shock syndrome. N Engl J Med 2005;353:877–889.PubMedGoogle Scholar
  223. 223.
    Swanepoel R, Shepherd AJ, Leman PA et al. Epidemiology and clinical features of Crimean-Congo haemorrhagic fever in Southern Africa. Am J Trop Med Hyg 1987;36:130–142.Google Scholar
  224. 224.
    Lima EQ, Nogueira ML. Viral hemorrhagic fever-induced acute kidney injury. Semin Nephrol 2008;28:409–415.PubMedGoogle Scholar
  225. 225.
    Hart CA, Bennett M. Hantavirus: an increasing problem? Ann Trap Med Parasitol 1994;88:347–358.Google Scholar
  226. 226.
    Nikiasson BS. Haemorrhagic fever with renal syndrome, virological and epidemiological aspects. Pediatr Nephrol 1992;6:201–204.Google Scholar
  227. 227.
    Grcevska L, Polenakovic M, Oncevski A et al. Different pathohistological presentations of acute renal involvement in Hantaan virus infection: report of two cases. Clin Nephrol 1990;34:197–201.PubMedGoogle Scholar
  228. 228.
    Peco Antic A, Popovic Roiovic M, Gligic A et al. Clinical characteristics of haemorrhagic fever with renal syndrome in children. Pediatr Nephrol 1992;6:335–338.PubMedGoogle Scholar
  229. 229.
    Huggins JW. Prospects for treatment of viral haemorrhagic fever with ribavirin, a broad spectrum antiviral drug. Rev Infect Dis 1989;11:S750–S761.PubMedGoogle Scholar
  230. 230.
    McCormick JB, King IJ, Webb PA et al. Lassa fever: effective therapy with ribavirin. N Engl J Med 1986;314:20–26.PubMedGoogle Scholar
  231. 231.
    Gambotto A, Barratt-Boyes SM, de Jong MD, Neumann G, Kawaoka Y. Human infection with highly pathogenic H5N1 influenza virus. Lancet 2008;371:1464–1475.PubMedGoogle Scholar
  232. 232.
    Wiwanitkit V. Renal insufficiency on presentation of bird flu infection: is it correlated to outcome? Clin Exp Nephrol 2006;10:87–88.PubMedGoogle Scholar
  233. 233.
    Lau YL, Peiris JSM. Pathogenesis of severe acute respiratory syndrome. Curr opin immunol 2005;17:404–410.PubMedGoogle Scholar
  234. 234.
    Farcas GA, Poutanen SM, Mazzulli T, Willey BM, Butany J, Asa SL, Faure P, Akhavan P, Low DE, Kain KC. Fatal severe acute respiratory syndrome is associated with multiorgan involvement by coronavirus. J Infect Dis 2005;191:193–197.PubMedGoogle Scholar
  235. 235.
    Ding Y, He L, Zhang Q, Huang Z, Che X, Hou J, Wang H, Shen H, Qiu L, Li Z, Geng J, Cai J, Han H, Li X, Kang W, Weng D, Liang P, Jiang S. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J Pathol 2004;203:622–630.PubMedGoogle Scholar
  236. 236.
    Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003;426:450–454.PubMedGoogle Scholar
  237. 237.
    van den Hoogen BG, De Jong JC, Groen J, Kuiken T, de Groot R, Fouchier RA, Osterhaus AD. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 2001;7:719–724.PubMedGoogle Scholar
  238. 238.
    Allander T, Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell A, Andersson B. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci USA 2005;102:12891–12896.PubMedGoogle Scholar
  239. 239.
    Greenwood B, Mutabingwa T. Malaria in 2002. Nature 2002;415:670–672.PubMedGoogle Scholar
  240. 240.
    Giglioli C. Malaria and renal disease with special reference to British Guiana. II. The effect of malaria eradication on the incidence of renal disease in British Guiana. Ann Trop Med Hyg 1962;56:225–241.Google Scholar
  241. 241.
    Marsh K, Greenwood BM. Immunopathology of malaria. Clin Trop Med Commun Dis 1986;1:91–125.Google Scholar
  242. 242.
    Hendrickse RG, Gilles HM. The nephrotic syndrome and other diseases in children in Western Nigeria. East Afr Med J 1963;40:186–201.PubMedGoogle Scholar
  243. 243.
    Ehrich JHH, Eke FU. Malaria-induced renal damage: facts and myths. Pediatr nephrol 2007;22:626–637.PubMedGoogle Scholar
  244. 244.
    Abdurrahman MB, Aikhionbare HA, Babaoye FA et al. Clinicopathological features of childhood nephrotic syndrome in northern Nigeria. QJM 1990;75:563–576.PubMedGoogle Scholar
  245. 245.
    Hendrickse RG, Adeniyi A, Edington GM et al. Quartan malarial nephrotic syndrome. Lancet 1972;1:1143–1148.PubMedGoogle Scholar
  246. 246.
    Boonpucknavig V, Sitprua V. Renal disease in acute Plasmodium falciparum infection in man. Kidney Int 1979;16:44–52.PubMedGoogle Scholar
  247. 247.
    Eiam-Ong S. Current knowledge in falciparum malaria-induced acute renal failure. J Med Assoc Thai 2002;85:S16–S24.PubMedGoogle Scholar
  248. 248.
    Maitland K, Levin M, English M, Mithwani S, Peshu N, Marsh K, Newton CRJC. Severe P. falciparum malaria in Kenyan children: evidence for hypovolaemia. QJM 2003a;96:427–434.PubMedGoogle Scholar
  249. 249.
    Maitland K, Pamba A, Newton CRJC, Levin M. Response to volume resuscitation in children with severe malaria. Pediatr Crit Care Med 2003b;4:426–431.PubMedGoogle Scholar
  250. 250.
    Akech S, Gwer S, Idro R, Fegan G, Eziefula AC, Newton CRJC, Levin M, Maitland K. Volume expansion with albumin compared to gelofusine in children with severe malaria: results of a controlled trial. PLoS Clin Trials 2006;1:e21.PubMedGoogle Scholar
  251. 251.
    Maitland K, Pamba A, English M, Peshu N, Marsh K, Newton C, Levin M. Randomized trial of volume expansion with albumin or saline in children with severe malaria: preliminary evidence of albumin benefit. Clin Infect Dis 2005;40:538–545.PubMedGoogle Scholar
  252. 252.
    Mehta KS, Halankar AR, Makwana PD et al. Severe acute renal failure in malaria. J Postgrad Med 2001;47:24–26.PubMedGoogle Scholar
  253. 253.
    Van den Ende F, Coppens G, Verstraeten T et al. Recurrence of blackwater fever: triggering of relapses by different antimalarials. Trop Med Int Health 1998;3:632–639.PubMedGoogle Scholar
  254. 254.
    Kline MW, Sullivan T. Schistosomiasis. In Textbook of Paediatric Infectious Diseases, 3rd edn. Feign RD, Cherry JD (eds.). Philadelphia, WB Saunders, 1992, pp. 2112–2119.Google Scholar
  255. 255.
    Sobh MA, Moustafa FE, El-Housseini F et al. Schistosomal specific nephropathy leading to end-stage renal failure. Kidney Int 1987;31:1006–1011.PubMedGoogle Scholar
  256. 256.
    Correia EI, Martinelli RP, Rocha H. Is glomerulopathy due to schistosomiasis mansoni disappearing? Rev Soc Bras Med Trop 1997;30:341–343.PubMedGoogle Scholar
  257. 257.
    Sobh MA, Moustafa FE, Sally SM et al. Characterisation of kidney lesions in early schistosomal-specific nephropathy. Nephrol Dial Transplant 1988;3:392–398.PubMedGoogle Scholar
  258. 258.
    Martinelli R, Noblat AC, Brito E et al. Schistosoma mansoni-induced mesangiocapillary glomerulonephritis: influence of therapy. Kidney Int 1989;35:1227–1233.PubMedGoogle Scholar
  259. 259.
    Turner I, Ibels LS, Alexander JH et al. Minimal change glomerulonephritis associated with Schistosoma haematobium infection-resolution with praziquantel treatment. Aust N Z J Med 1987;17:596–598.PubMedGoogle Scholar
  260. 260.
    Dutra M, Martineiii R, Marcelino de Carvalho E et al. Renal involvement in visceral leishmaniasis. Am J Kidney Dis 1985;6:22–27.PubMedGoogle Scholar
  261. 261.
    Caravaca F, Munoz A, Pizarro JL et al. Acute renal failure in visceral leishmaniasis. Am J Nephrol 1991;11:350–352.PubMedGoogle Scholar
  262. 262.
    Yap HK, Woo KT, Yeo PP et al. The nephrotic syndrome associated with filariasis. Ann Acad Med Singapore 1982;1:60–63.Google Scholar
  263. 263.
    Gelman R, Brook G, Green J et al. Minimal change glomerulonephritis associated with hydatid disease. Clin Nephrol 2000;53:152–155.PubMedGoogle Scholar
  264. 264.
    Covic A, Mititiuc I, Caruntu L et al. Reversible nephrotic syndrome due to mesangiocapillary glomerulonephritis secondary to hepatic hydatid disease. Nephrol Dial Transplant 1996;11:2074–2076.PubMedGoogle Scholar
  265. 265.
    Costa RS, Monteito RC, Lehuen A et al. Immune complex-mediated glomerulopathy in experimental Chagas’ disease. Clin Immunol Immunopathol 1991;58:102–l14.PubMedGoogle Scholar
  266. 266.
    Eckstein CW, Kass EJ. Anuria in a newborn secondary to bilateral ureteropelvic fungus balls. J Urol 1982;127:109–l12.PubMedGoogle Scholar
  267. 267.
    Barrane FE, Hurwitz RS, Rojas EL et al. The role of percutaneous nephrostomy in the management of obstructing candidiasis of the urinary tract in infants. Urol 1988;140:338–341.Google Scholar
  268. 268.
    Stocker M, Caduff JH, Spalinger J et al. Successful treatment of bilateral renal fungal balls with liposomal amphotericin B and fluconazole in an extremely low birth weight infant. Eur J Pediatr 2000;159:676–678.PubMedGoogle Scholar
  269. 269.
    Weintnib PS, Chapman A, Piecuch R. Renal fungus ball in a premature infant successfully treated with fluconazole. Pediatr Infect Dis J 1994;13:1152–1154.Google Scholar
  270. 270.
    Levin M, Kay JDS, Gould JG. Haemorrhagic shock and encephalopathy: a new syndrome with high mortality in young children. Lancet 1983;2:64–67.PubMedGoogle Scholar
  271. 271.
    Chesney PJ, Chesney RW. Haemorrhagic shock and encephalopathy: reflections about a new devastating disorder that affects normal children. J Pediatr 1989;114:254–256.PubMedGoogle Scholar
  272. 272.
    Levin M, Pincott JR, Hjelm M. Haemorrhagic shock and encephalopathy: clinical, pathologic, and biochemical fea-MKs. J Pediatr 1989;114:194–203.PubMedGoogle Scholar
  273. 273.
    Smith OP, White B, Vaughan D et al. Use of protein-C concentrare, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet 1997;350:1590–1593.PubMedGoogle Scholar
  274. 274.
    Vats A, Randhawa PS, Shapiro R et al. Quantitative viral load monitoring and cidofovir therapy for the management of BK virus associated nephropathy in children and adults. Transplantation 2003;75:105–112.PubMedGoogle Scholar
  275. 275.
    Antiviral therapy and prophylaxis for influenza in children. Pediatrics 2007;119: 852–860.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  • Jethro Herberg
  • Amitava Pahari
  • Sam Walters
  • Michael Levin

There are no affiliations available

Personalised recommendations